<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:51.1pt;left:74.6pt;line-height:25.2pt"><b><i><span style="font-family:Times New Roman,serif;font-size:25.2pt;color:#8c3a2a">toxins</span></i></b></p>
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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==">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<p style="top:102.1pt;left:35.7pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Review</span></i></p>
<p style="top:114.6pt;left:35.4pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Toxic Animal-Based Medicinal Materials Can Be Effective in</span></b></p>
<p style="top:133.4pt;left:35.4pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Treating Endometriosis: A Scoping Review</span></b></p>
<p style="top:170.4pt;left:36.0pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Su-In Hwang</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup></p>
<p style="top:170.4pt;left:113.0pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Young-Jin Yoon</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,2</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Soo-Hyun Sung</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">3</span></b></sup></p>
<p style="top:170.4pt;left:296.4pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Ki-Tae Ha</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">4</span></b></sup></p>
<p style="top:170.4pt;left:365.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and Jang-Kyung Park</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,2,</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">*</span></b></p>
<p style="top:425.9pt;left:55.5pt;line-height:7.9pt"><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span><span style="font-family:SourceSansRoman.613wght,serif;font-size:7.0pt">&#xfffd;</span></p>
<p style="top:433.1pt;left:55.5pt;line-height:7.9pt"><b><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></b></p>
<p style="top:451.0pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Citation:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> Hwang, S.-I.; Yoon, Y.-J.;</span></p>
<p style="top:462.9pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Sung, S.-H.; Ha, K.-T.; Park, J.-K.</span></p>
<p style="top:474.9pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Toxic Animal-Based Medicinal</span></p>
<p style="top:486.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Materials Can Be Effective in Treating</span></p>
<p style="top:498.7pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Endometriosis: A Scoping Review.</span></p>
<p style="top:510.6pt;left:35.6pt;line-height:7.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:7.0pt">, 145. https://doi.org/</span></p>
<p style="top:522.6pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">10.3390/toxins13020145</span></p>
<p style="top:546.4pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Received: 28 December 2020</span></p>
<p style="top:558.4pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Accepted: 12 February 2021</span></p>
<p style="top:570.3pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Published: 14 February 2021</span></p>
<p style="top:595.7pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Publisher&#x2019;s Note:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> MDPI stays neutral</span></p>
<p style="top:607.6pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">with regard to jurisdictional claims in</span></p>
<p style="top:619.5pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">published maps and institutional af&#xfb01;l-</span></p>
<p style="top:631.4pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">iations.</span></p>
<img style="position:absolute;transform:matrix(.1511808,0,-0,.1511808,-164.20479,803.6891)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAfQAAACvCAIAAACEirtdAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAY4UlEQVR4nO2dT2sVyRqHXTTcnaAMiJBdIO5CUAgirmYIswqBXIK4
cOEouBlmEYK4cTG6mIVuNIgrwWQj5K7MJzDfQL+B32D8Brm/m+L2Pbe7T/Vb/9+u
/hXPYv6cnNM5qX76raq33rp0/v/t6Pj4n3t7zT/+QQghZBJA2lB3R+aX2n/6+vXr
rc3N4ldJCCHEAwgcGu/K/cvZ2U/XrhW/OEIIId5A45D5/+QO2dPshBBSAZC5id//
I/f+bMz6zY17D+7/+dcLQgghaoGooeuOwKH0/8j96Ph48b9evnrl6fNnJ6f/IoQQ
Mgkgbah70eQQ+6VObgzNTgghkwPqXjQ5xH6pMxtT/BIJIYR40Jmf+T+533twv/j1
EUII8QACXyr3P/96Ufz6CCGEeACBU+6EEFIblDshhFQI5U4IIRVCuRNCSIVQ7oRM
gI+fjnA/PnzyyGxBBNdXVga3m1++esW84Odft/Dip8+fvXr7uvj1k/xQ7oQo5d2H
97/v/wFHL/O4E20RkeK/F8nDTOWOWAa/HYIadHc7iJVM0QbcacUvm8wB9DT0utUb
a+FCXxba44HBzefVMwu5Q+WIgLZ3dyyDWSH4cRMB4d6g7klc0Klu372TyOmDlsdN
wW5cK9XKHUIfLJAW/fbA3Yg4i9OaJAQEH1HmXvxAIE/F10dtckfsg57aqYiWB9yc
iIM42iVOlNU6FV8xlcgdgTPEWsTpyyzP+4TYQadNPbL0AF3346ej4l8OCWfyckfg
o/AOMeDCcHnFvyKikE5RJ1UgOuEAtAImLHc949nRW4WKJy0I2NNlwkSEIfzUmaTc
p6J1Kp50QB8ImTz8ZWtr/+DgzeHhl7Ozr9++nS9p+L/gxcuXvz1+3D81Uw4eQswU
mC4TkzsuaXJa7yieA97Z8vOvWx59BnaGpi0qH21///jx+fQUovc4+B6PIgYlE2Uy
cn/34X3OFOCkrN/c4HLrrPj46ch1ZWh1bQ1O//79u7fTB5uxvGuPffjkUfHvkLgy
DbmjbynJhIkFfh0edDUTYHanSXZo/ej4OK7TOw3PDDw5nAJ5DDuKf5PECe1yR4Sr
NhkmHNzzDOHrxsnsGbS+2P7+8WP/4IB+rxXVcn/6/Fm6gB030i9bW7t7ewhhLGAM
i5fhxYkug3OaFeNkdnQ22Dab2duGKB49nH6vD71y397diatRk2mAyMh7bQo/+Pn0
FDeh/GaQ3zNMO6sMudlvbW6GrJdGaW8OD4WzNPT7VNAod4/Vp2Ug4obQYeQU98OX
szO8eaygHiKg32tCaHYMDYsE7P2GB4wwb5LLRZNAndyjbPFADALtZouG8EFRLH/5
6hWmFdeBMOsxcIb9+/fv6HhmHInut7u3F/iGeMwIc2k4l6gfXXKH2gIn2RF65FyS
6jQMEQJnbPDrMxF+6jx88kgSf2DkF9LZXrx8uewWCAxrJKusDET0o0jugWaHVQPv
llgNt5ZHKjHDojpAN5aYPal/8f6BCfKIkEZ/i+srK5xI1IwWuUNn3ipEqKJE64vN
KQmBfq8DyG50B3W42dHbJbFOYAeW+P323TvFv3OyDBVy9zY77pM3h4eBnThpw33o
PRdPv0+O0U3U4WZH293bk/Sf8A+S+J2ziGopL3fv2Rh0cSVpBqNt2fQo/V4T0Nzo
HzTKEFPYedDrwj9rdP4dNy8nZ3RSWO5+Zkf4kyi7MV2T55nR71NEMiETZakfHSmn
3NFGF5CY+a6TknJ/9+G9h9mhyOjVlPI0eZ5ZB6Yl6Gf08A2EwFF6UX65o9+OxiXF
d7OTPsXk7lpNyQA5RumvBRvCN9fKq0w7Uw7ClNGIJGIXyiz384vsAHunXb+5Ufyv
QDoUk7vHHtSCCexxG4IvV78z7Uwz9i1L4YmJnZZtQXWxjS6uMnjXRhm5u9aNwe1R
jdlNw93uOgXP4Egno2F79IQuSSokHgBxPxTNntrL/qmNAnKXJBV0zF68rFKKJpnK
7MCaHgqxh+3h+eaDbXQTU4pEstHJGU4eqiK33F0XUWs1u2kefufgVxUfPx3Z+3O6
3rssvxaPk3QpwvakXqbNqCK33J2m2us2u2mufufkuyrsZWRSr/+3hcMM4YXDRhu6
qz14Z+fUQ1a5j6aLZYt6VDVXv3PPtx7sGV8Tzdm1N3vwzm0Zesgn99F1pw6VraDa
G/zuVKWAkzMasHfpCtJ2B5s9eGfkoYd8cneakFFeMSZFc8qP5OSMBuwj0VjjTsjU
HP4Vwu7eXsTieva9eOyZSsgkd6fSYLWGPKNNkuLWwsyZ4ljmZCLuWvKrWjFILL/b
d8lyZkYJOeQ+mlGQ6K6YYnMqMfbuw/viHWi2oFdb/jSxhp5Oz/tRIia/W2YRmTOj
hBxyl6+jRt/LN8XGo+gngX27Rqxu7F1PdJCISfeWRPvrKyvF/zrkJIPcnRLbJ1fr
MUUbzTZbhMF7KSy7rCOOPtXK3T6k4LS7BpLLXXhScDPjqfZ+w0NO+KUxeC+FJUEg
YsUutXI/t9YvYzaXBtLKXZ7+mGjD9HSbsDhUw+C9EJa/SMS8FM1yt8wfcrVfA2nl
Li8QxgmZThut49HC4D0/9qglYjfQLHfLtbFPaiCh3OVJMomKK029yW9sTnFmpnPb
LBI33Uuz3C1FgFkhUgMJ5W4vu7EIM2SWNeG2VXzVxXvSrLD07WzRcXG5W9ZUmTCj
gYRyHz1S0sB1VEuTHD/Peyk/luzeiKup57rlfm5dUy3+NyKp5P7q7Wthh2PYbm/C
4J2ltHNCuZtGuWsmldyFGZAM20ebMHjnElZObt+9s+wPETc1QLncLWv+xf9GJJXc
hUupDNtHm3BPE77w4p1pPliS3CPmQZ6rl7slG5Kp7sVJInfhQXrRj3nEffXm8BD3
AwYEphge/gH/CvC/oj9I8IYI08z743cxn7h/cIB/xWVEvMntZ6rxdsoP5W4a5a6Z
JHIXprfHGsAeHR8Lt/ysrq1BlIG1WM3xN8KpcPR+iD5wf5a9CF8Lvvbi/WkmUO6m
Ue6aSSJ3SZ4M5Bjet6B1pzMuFnu5x00IrdsrWS/jp2vX8IMhipfUfV29sVa8P80E
yt00yl0z8eUuLDmA4DekVyGYDa9zjWuQCxcBuLye1zLFex8vhU+XfAR3M+WBcjeN
ctdMfLkLz+UImRuBIgM924InxOiV4AEgr/Qyil+CEAYNkjd/+vxZ8S41B5gtY5rl
s4r/jUh8uUuSIEPmZISpgXLwnLD43fX06nR+l0xAcdo9D8xzN41y10x8uUsm3L3T
26ObvfX7YC5NCrN7fwOSnBnW9MgD5X5+cXdQ7pqJLHf72WMtfkPXuEeOdRis9+S3
fCrE9SQ2YZH34l1qDljmHllbpuHavg4iy91SLW8Rj7wRp/OJ/OjEXPITM7xxWngQ
TruzvHsGLP08ShpY2zTLnVUhlRNZ7pJKkH69X7iRp/lvMjvUjMjCIE9Lbydn8CyR
J1maZPb24+R59643m+SSmKWQAfsINeKxM+iQbb8yONl8sVuCwB0enWZ58HDtRwOR
5S7ZvuSxMVUYtDbLZzxxv9kfDxgW4Gfb21IYMd3a3FyW+ob/bh9qeOTaS87O5iE4
ebAU2Eh68oyT3OPmZXYaT2JSTmS5W/J/R/1racKwfTSLfDBbvKN10yQxMsxuj9GW
TSX5baE6lz1yeF/lwdLVA/dw2JseuVs+l8NHDUSW++qNcSd6dDjJbLsw/2RxwmRQ
6+ey2fZlCTad1hlHe2vdNEmyEKc782BJmIl7GFOnKZG7fYKIm+k0EFnukg7nOvEn
XNgUTnSas0mXad00SZKMfPxh3i1Q66ZJplwp9zzYq+OlK3eqRO6WwTRTZZRQQO4R
u1GLU9o4nhb2e08yJyO/e82amPzy7G81emE8lSkP9jVV1zxXeVMid8s9wqMFlBBT
7sKqMq7dSLKK6F2zpd/sWzMMScfd9ib5hov3qplgmXaPmxDp2gFSy91eppQ1MJQQ
U+6SJHcPLUom3COOgiVTH0lXzOyNcteDPfE3kVg1yN0+b8kJdyXklrvHNgpJJ47Y
cSWLlukG3aNN8qgr3qtmgn2oGr2Qi2nF5W4f2t6+e6f434UYtMtdck5F3EkSSbph
0gwze5NMUhXvVfPBUh4yUT8pLnf7DfL7/h/F/yjEoF3ukkmS/NU8KHdisBe4ThG8
l5W7vQrI5atXOCejB8q92yh34oS9DGr0rlJW7vbUNebJqIJy7zbKnThh2c3UXKTN
RCw1c15U7qNzpCxapwrKvdsod+LEx09HljozTewK7wXlbu973D2nDe1yl2SdN1Gz
ZSRyj5hW79okh4cU71Vzwx68x5VsKbmPnuLLejLa0C53YW+OOPKVjBXixmJOTfJt
FO9VcwPBu33mPeLkTBG5j07IMANSITHl/urt69He9tO1a64dS1IMIGKRVUnyZaIU
Zkmj3HUyei58rD6TX+6Sc3I4266QCdSWkRx84bpl9Oj42BJJSX4Lp0AMD4xYMRTl
rpbRetfeRwe7doCIcpccI8wq0zopIHfX8enoZF/jOCAwEy+WwpDRq9mYNwwvDMmq
kJpB9GpfWW1i7G3OLPfR0Or6ygpz23USWe72mUe/Dic8hkk4D96JRKD4/v0meZzI
Z1E7JYtDFE+5K0dyzGTganxOuUtqX3MdVS0FTmLy6NySFBFoWlIpfrC/wtSLVyV8
nEhG2bikwflK/KxHsTNJJg83kpTFXpAg3O/Z5C4xOydkNBNZ7jDLaIfwKKkoKeZl
/G7pzQi07WNMKL59PAhPuMYNYInfR49RdZ2E5f2mn9HMGYP3/EwGuUvm2RseyqGe
yHIfTfhtfNMGJDkzrTE/n54uOhfKRszrVDpYfsy8mbtfHDTgo3EBEhG7fhWSxQBW
birOq7evRyffG9/11dRyxy0gMTvLyOgnstztZ4+1ePRpYfAeQmfWXhi8h+B64qDk
PTkHqoHRzEgDntau+QX4ETmuHWx0rNmaHQ+w4l8ysRNZ7sLDmPxGi5K41Zt+3WBz
2mq6T3QdmEsS8BvmQapB6HcMSQtWs1hskhUdA89amgSR5Q4kA1K/HZ6IceSTM05A
4oPLm8KzuT3wGJJLcnh4gKoqtnd3hP1h/+Agbn0xp4a4QTIVY+C831SIL3dJwoz3
br1lySeBZreMXlNMB/mdLiKZJmKqjDYkKQaGIiE8nijygJ1mnxbx5S5ZU20CqsFA
xBHjd0kCZVy/w9F+v7vkzR8+eVS8S5EOcr83MXa6yRvGgk6hEs0+LeLLXVI+rAlL
9YUco8y/y5ezcL9FeaJ4VxwTThBxmUsnwvn3PIo30bpTf7589QoX6idHfLmfyKbd
w+so4fHgLdzBjamjt4T9GJqkt6sksRJfe/H+RJYBv0vui0XQvdFLPTa7LWvCDN0O
11dWGDRMkSRyl2zSaxaSykMaFC9fC2pvGO9JIVwzFO/0UNnd2wssWikpy9ew7Kp6
hPnvfdDD0es6uzeE7eu3b7hH0An9FqvWb24wn32iJJG7cBAasSo6nAtlIypBgNzv
xLg30LnxAte0X0szG6PwtoOPFlwGLgY3VawHmOT75JSofiBKScaBPTpB70LfA9A9
hoMd0Fvwv8y9EPJBDXc7T5wkckcPlnQdj9ru82zCu5QR1lQQJh0U5PrKCifZp04S
uZ+IZ2YKnlc3lSYshMBCH9Pi1dvX+JMVl/gg27s7DBQqIJXc5dvzSstTexOugHFO
Zoo8fPLIbxY+Ees3N7h2Wg2p5H4iy5lpGLxbm7D4cMM5mcmCP9y9B/eLK/76ygqL
ClRGQrkL915HPDu4viYsXsaNqVOnoOJXb6xx2FclCeUuLCLWRE2bqanJyw5z7asO
oHh4Ns9cPB4kiAnYcyomodxPxMuqy+p2zbwJ8/dZLKw+Xr19jYGv5NAPD6fjrsQj
hPN41ZNW7sJSBE2MDauVNUkNSAPH1BWD4S/+vgixQ0QPoa/f3Lj34D7j9FmRVu4n
siKRhvCD4atp8lLyDNtnBW5JuB6aRlyPO2sZiM3xGmNzPB6KXzYpQnK5y4N3Ts60
Tb63kGE7IWSQ5HI/cSl56lfovLImr6/NsJ0QsowccpenzTQXR9KUtmvJJs+QYdhO
CLGQQ+4njsU0ZrutyenU1vWbG8V7DyFELZnk/vHTkdNyf8TyjVNpf//44VS7mNvE
CSEWMsm9/0l2JKff1dRczb69u1O86xBCNJNP7icuh8E3MytL4HQ+DsZA3IFCCLGT
Ve6ukzMIZufgd9eTz7gVhRAySla5n1zsq3YSWfV+dzU7D8chhEjILfeTixrWrn6v
cnOT6zx7wwwZQoiYAnI/cdnWZKhvfdXD7JevXuFUOyFESBm5Q1KudU3h9y9nZ6Wd
HKfhQbW65lzWlbmPhBA5Nrl7IE/Re/fhvcfRBBUUFzs6PpbvVGqRb0aVV2ojhMyH
ULk3LgEmXunh9929vekuse4fHHh8pQ+fPBJ+pcKjawkhcyOC3J0W/Zx2NrWsrq1N
bgoeF+w6yW6QH6H38dNR8aM4CSE6iSD3xrGglXew+eLly6mE8PJCjx2cDkd12iNG
CJkVceTumtfh7XeE8MpXWXF5fgF742h2vzEQIWQmxJE7uH33jlxMgZPFu3t7ChPh
cUmuG5QWcTK769ZfQsjciCb3xr3aOF4fMmUMkypRfKDWG0ezc0KGEDJKTLnD1K7n
N/rlzywCqxZca8VHB2q9cX8oPn3+rHi/IYQoJ6bcweqNNSdPGb+HzzDc2tw8Oj7O
ttyKD8LHec+tt+DB5mp2v+0ChJC5EVnujVflcY/9q8vY3dtLZ3njdHxElEvFI81j
D2qsL4oQUjfx5d74HvXpWn/GDsLq/YODz6engfPy+HG8Cd4qPE5fZP3mhkfdmLhf
ESGkYpLI/fLVK351UQKXWC38srX12+PHL16+fHN4+OXsrOXrt29g8b/gBXgZXowf
SfSl+1Xx5WZUQoicJHJvvBZXT/47BV/xzIPfVMwJs9oJIY6kkntzsbjqXbEWsW3x
ryY627s7fl9IeE4R0QMGhYsjRTsYRILBQeStzc3+64+OjyXXgJf1fzbuxCMpTkK5
N2F+rymExy/iXU6ZZq8MyNpvMR8/2CkvOpgEPJqbixf0fwpyL/7NkLiklXsT5veT
i1OcJq02XLy8xGMflgarDz+5mwabL/odEf3gY8BSYhr/azCXjGF7fSSXe3NRmSDE
7/jZic7S4LIDf/Fqxi6kJUTu5xfHAyy+G/61/5o3h4dOn255PZkuOeTeBMfvJxeb
dyaUCIhL9VtPXpyNodmrJFDuaIunejlF4vjB/ivtkT6ZLpnk3sTwu1E8wmG1MxW4
sMBovTW72t+RBNKX+9dv337Z2urw2+PHg1E5Wmcb3f7BQf81g3PogxVVw+tnEJ3k
k3sTye9mvuL3/T9UBbbrNzf8tm7R7HOjL3fLYiY83tdx/7QAycrq4FtxHbVissq9
CdjftMyD27s7BYvf4gHz8MmjwBmYRbhTqXqc5N4Mibsv91ubm31xf//+fXG+ZXCr
NtdRKya33BuvalkSy0Oy2Y6Kvn33TlynGya6bkyccJV7fy5l8GDewaPk28cA11Fn
SAG5G/y24Ev4868XeHOIPuLkBgYHRuje6ep2Pn46wvsX7w0kA65y70fcg+H2spXV
1bU10P9fXEetnmJyb3yLZ7lKEzrGQAG6//nXLXwisEzWmxeA7d0d/MjT588S2XyR
KEWPyVRwkrvTi5ftTvp8etr/71xHrZ6Scm8upmgg0NT21AxGA8U7AclJ39eIzU2Z
gUXeHB72Y3aE24t5kH2EJwxzHXUOFJa7wbvoyqR59+F9tkUCogfvPHcY2W72ZsnK
ar9xHXUOqJB7czGpnWECRA9TL6tAvPGWu/Co3sGV1cXGddSZoEXuhtt370RPQdEG
nmGqMvRJZuKWH+izbGXVNK6jzgddcm/ibfJUCH6pCVVQIInoyx3C7RfgtQh6NPQe
XFk1LdYhkUQ/6uRuuL6yEj0XvqzWNVdNIDlxTYAZ3Hw0Ovk+uLLKddRZoVTuhgoU
T62TDq557oNZ6v1Nqh0Giw2MPhJITaiWu8EofnITNcprnJFSuMod9BPVR39ksNR7
8d+d5GQCcjfAktu7O5NYbv3zrxecWyfL8JC7x49Q7mQycm8x9RcVBvJ48Dx88oh7
TYkdD1P3a/9S7mSU6cm9BdGxBsvD6bgMVoYhQlzlPpjaSLmTUSYs9xZT0itiJWHh
3Mu9B/eZsU5ccZI7HD1Yq310QZVyJzXIveXy1SsQPZwL80aP6BGhP33+zNSbLP6b
kukizHO3V4kZzXuh3ElVcu8A17f1HaF7IFyPxSAALzYqN7UkmfRCYhF+hqqkfgDl
TmqWux2j/pbi10NmQuryAwbKncxX7oQUwVvuf//4MTrV3kK5E8qdkKx4yP3L2dn+
wYFTwS/KnVDuhGRldW0N5hXi/Sl4EkR8NzJFKHdCCKkQyp0QQiqEcieEkAqh3Akh
pEIod0IIqRDKnRBCKoRyJ4SQCqHcCSGkQih3QgipkEvCOkSEEEKmAsT+b9alGfaK
qT4aAAAAAElFTkSuQmCC">
<p style="top:684.3pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Copyright:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> &#xa9; 2021 by the authors.</span></p>
<p style="top:696.2pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Licensee MDPI, Basel, Switzerland.</span></p>
<p style="top:708.1pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">This article is an open access article</span></p>
<p style="top:720.1pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">distributed</span></p>
<p style="top:720.1pt;left:76.6pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">under</span></p>
<p style="top:720.1pt;left:101.5pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">the</span></p>
<p style="top:720.1pt;left:117.5pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">terms</span></p>
<p style="top:720.1pt;left:141.3pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">and</span></p>
<p style="top:732.0pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">conditions of the Creative Commons</span></p>
<p style="top:743.9pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Attribution (CC BY) license (https://</span></p>
<p style="top:755.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">creativecommons.org/licenses/by/</span></p>
<p style="top:767.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">4.0/).</span></p>
<p style="top:200.4pt;left:167.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">1</span></p>
<p style="top:201.7pt;left:180.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Department of Korean Medicine Obstetrics and Gynecology, Pusan National University Korean Medicine</span></p>
<p style="top:212.4pt;left:180.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hospital, Yangsan 50612, Korea; hwangsi1216@gmail.com (S.-I.H.); yyj@pusan.ac.kr (Y.-J.Y.)</span></p>
<p style="top:221.9pt;left:167.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">2</span></p>
<p style="top:223.2pt;left:180.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Division of Clinical Medicine, School of Korean Medicine, Pusan National University, Yangsan 50612, Korea</span></p>
<p style="top:232.6pt;left:167.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">3</span></p>
<p style="top:234.0pt;left:180.7pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Department of Policy Development, National Development Institute of Korean Medicine, Seoul 04554, Korea;</span></p>
<p style="top:244.7pt;left:180.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">koyote10010@nikom.or.kr</span></p>
<p style="top:254.2pt;left:167.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">4</span></p>
<p style="top:255.5pt;left:180.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Department of Korean Medical Science, School of Korean Medicine, Pusan National University,</span></p>
<p style="top:266.2pt;left:180.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Yangsan 50612, Korea; hagis@pusan.ac.kr</span></p>
<p style="top:277.0pt;left:166.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">*</span></b></p>
<p style="top:277.0pt;left:180.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Correspondence: vivat314@pusan.ac.kr; Tel.: +82-55-360-5978; Fax: +82-55-360-5890</span></p>
<p style="top:301.9pt;left:166.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Abstract:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Animal toxins and venoms have recently been developed as cancer treatments possessing</span></p>
<p style="top:315.0pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">tumor cell growth-inhibitory, antiangiogenesis, and proapoptotic effects. Endometriosis is a common</span></p>
<p style="top:327.9pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">benign gynecological disorder in reproductive-age women, and no de&#xfb01;nite treatment for this disorder</span></p>
<p style="top:340.8pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">is without severe side effects. As endometriosis and malignant tumors share similar characteristics</span></p>
<p style="top:353.8pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(progressive, invasive, estrogen-dependent growth, and recurrence), animal toxins and venoms are</span></p>
<p style="top:366.7pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">thought to be effective against endometriosis. The objective of this study was to outline studies</span></p>
<p style="top:379.7pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">using toxic animal-based medicinal materials (TMM) as endometriosis treatment and to explore</span></p>
<p style="top:392.6pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">its clinical applicability. Preclinical and clinical studies using TMM were searched for in four</span></p>
<p style="top:405.6pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">databases from inception to October 2020. A total of 20 studies of TMM on endometriosis were</span></p>
<p style="top:418.6pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">included. In eight clinical studies, herbal medicines containing TMM were effective in relieving</span></p>
<p style="top:431.7pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">symptoms of endometriosis, with no side effects. In twelve experimental studies, the main therapeutic</span></p>
<p style="top:444.5pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">mechanisms of TMM against endometriosis were proapoptotic, antiangiogenesis, estrogen level-</span></p>
<p style="top:457.5pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reducing, and possible anti-in&#xfb02;ammatory effects. TMM are thus considered promising sources for</span></p>
<p style="top:470.5pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">the development of an effective treatment method for endometriosis. Further studies are needed to</span></p>
<p style="top:483.5pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">clarify the therapeutic mechanism of TMM against endometriosis and to provide suf&#xfb01;cient grounds</span></p>
<p style="top:496.5pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">for clinical application.</span></p>
<p style="top:521.4pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Keywords:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> endometriosis; toxic animal-based medicinal materials; Hirudo; Eupolyphaga; Scolopen-</span></p>
<p style="top:534.4pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">dra; Scorpio</span></p>
<p style="top:559.3pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Key Contribution:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Toxic animal-based medicinal materials have traditionally been used in Chinese</span></p>
<p style="top:572.2pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">medicine for blood-activating and stasis-dispelling purposes. This study reviewed preclinical and</span></p>
<p style="top:585.2pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">clinical studies of toxic animal-based medicinal materials for endometriosis treatment.</span></p>
<p style="top:632.2pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">1. Introduction</span></b></p>
<p style="top:647.8pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Endometriosis is a common estrogen-dependent, chronic in&#xfb02;ammatory disease expe-</span></p>
<p style="top:660.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">rienced by 10&#x2013;15% of reproductive-age women [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. It is de&#xfb01;ned as a disease in which</span></p>
<p style="top:672.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">endometrium-like tissue exists outside the uterus [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Endometriosis negatively affects</span></p>
<p style="top:685.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the quality of life and well-being of women of childbearing age owing to distressing</span></p>
<p style="top:697.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and debilitating symptoms and complications [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The most common clinical symptoms</span></p>
<p style="top:710.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">are dysmenorrhea, pelvic pain, infertility, and various clinical symptoms, such as dys-</span></p>
<p style="top:723.0pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pareunia, anal pain, and abdominal and adnexal masses [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Hypotheses on the origin</span></p>
<p style="top:735.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of endometriosis occurrence include endometrial origin due to retrograde menstruation</span></p>
<p style="top:748.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and non-endometrial origin, such as coelomic metaplasia and lymphatic and vascular</span></p>
<p style="top:760.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">metastasis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">7</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The interaction between endocrine, immunologic, pro-in&#xfb02;ammatory, and</span></p>
<p style="top:814.3pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145. https://doi.org/10.3390/toxins13020145</span></p>
<p style="top:814.3pt;left:414.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">https://www.mdpi.com/journal/toxins</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:536.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 of 21</span></p>
<p style="top:95.8pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">proangiogenic processes appears to be involved in the development of endometriosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In</span></p>
<p style="top:108.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">addition, endometriosis is a benign disease, but it displays similar features to malignancy,</span></p>
<p style="top:120.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">such as progressive, invasive, estrogen-dependent growth, and recurrence [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">9</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:133.4pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Conventional treatments for endometriosis include analgesics, combined oral contra-</span></p>
<p style="top:146.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ceptives, gonadotropin-releasing hormone agonists, and surgery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">11</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. However, there</span></p>
<p style="top:158.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">are limitations such as unpleasant and sometimes dangerous side effects and high recur-</span></p>
<p style="top:171.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">rence rates [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Thus, patients with endometriosis seek traditional Chinese medicine treat-</span></p>
<p style="top:183.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ments to cure the primary lesions and relieve symptoms, with fewer side effects</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. In</span></p>
<p style="top:196.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">traditional Chinese medicine, &#x201c;blood stasis&#x201d; is considered the basic etiology of endometrio-</span></p>
<p style="top:208.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">sis, and thus treatment is aimed at removing the stasis by promoting blood circulation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:221.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In east Asian countries, animal-based medicinal materials, which eliminate blood stasis and</span></p>
<p style="top:233.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">facilitate blood circulation, have traditionally been used to treat diseases. In Korea, there are</span></p>
<p style="top:246.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">records that such materials were used to address gynecological diseases caused by blood</span></p>
<p style="top:258.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">stasis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. It seems that animal-based medicinal materials were used mainly in China,</span></p>
<p style="top:271.5pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">where such substances are widely in use to treat various diseases such as rheumatism [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">],</span></p>
<p style="top:283.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">kidney disease [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], gynecological diseases [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], and cardiovascular and cerebrovascular</span></p>
<p style="top:296.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">diseases [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:309.2pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Venomous and poisonous animals have long been an area of interest in the treatment of</span></p>
<p style="top:321.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">diseases. Animals produce toxins in specialized glands or cells to protect themselves from</span></p>
<p style="top:334.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">predators and to predate on other animals [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Animal toxins include &#x201c;poison&#x201d;, which</span></p>
<p style="top:346.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">is produced by specialized cells or tissues and transmitted via ingestion or contact, and</span></p>
<p style="top:359.4pt;left:165.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x201c;venom&#x201d;, which is produced in tissues or organs and delivered parenterally via specialized</span></p>
<p style="top:371.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apparatus such as stingers, teeth, and nematocysts. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Animal poisons and venoms are</span></p>
<p style="top:384.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">composed of different classes of molecules, and they contain abundant proteins, peptides,</span></p>
<p style="top:396.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and neurotransmitters [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Although our understanding of the complexity of animal</span></p>
<p style="top:409.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">toxins is still limited, recent studies have shown that animal toxins can be developed as</span></p>
<p style="top:422.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cancer treatments because of their ability to inhibit cell growth, inhibit angiogenesis, and</span></p>
<p style="top:434.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">induce apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:447.2pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Considering the pathophysiology of endometriosis and the treatment mechanism of</span></p>
<p style="top:459.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">animal poisons and venoms identi&#xfb01;ed in previous studies, various animal poisons and</span></p>
<p style="top:472.3pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">venoms are thought to be effective against endometriosis. Recently, preclinical and clinical</span></p>
<p style="top:484.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">studies investigating the effects of animal poisons and venoms on endometriosis have been</span></p>
<p style="top:497.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">reported. However, as far as we know, no review articles on studies using toxic animal-</span></p>
<p style="top:509.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">based medicinal materials to treat endometriosis have been published. Therefore, in this</span></p>
<p style="top:522.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">study, we outline the use of toxic animal-based medicinal materials for endometriosis and</span></p>
<p style="top:535.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">explore the possibility of its clinical use.</span></p>
<p style="top:557.5pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2. Materials and Methods</span></b></p>
<p style="top:570.9pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.1. Scope of Toxic Animal-Based Medicinal Materials</span></i></p>
<p style="top:586.4pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">There are 99 animal-based medicinal materials with seven speci&#xfb01;cations (Korean</span></p>
<p style="top:599.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Pharmacopoeia, Korean Herbal Pharmacopoeia, Chinese Pharmacopoeia, Japanese Phar-</span></p>
<p style="top:611.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">macopoeia, Japanese standards for non-Pharmacopoeial crude drugs, Taiwan Herbal Phar-</span></p>
<p style="top:624.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">macopoeia, Democratic People&#x2019;s Republic of Korea Pharmacopoeia) from &#xfb01;ve northeast</span></p>
<p style="top:636.8pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Asian countries [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Among them, the following 10 toxic animal-based medicinal materials</span></p>
<p style="top:649.2pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">were selected by identifying toxicity [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]: Vespae Nidus, Tabanus, Mylabris, Agkistrodon,</span></p>
<p style="top:661.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Bufonis Venenum, Hirudo, Scolopendra, Eupolyphaga, Scorpio, and Gecko.</span></p>
<p style="top:684.2pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.2. Literature Search Strategy</span></i></p>
<p style="top:699.7pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">We searched the following databases from inception to October 2020: MEDLINE,</span></p>
<p style="top:712.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">EMBASE, one Chinese database (China National Knowledge Infrastructure (CNKI)), and</span></p>
<p style="top:724.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">one Korean database (Oriental Medicine Advanced Searching Integrated System (OASIS)).</span></p>
<p style="top:737.4pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The search words were &#x201c;Vespae Nidus OR Nidus Vespae OR Bee venom OR Tabanus OR</span></p>
<p style="top:749.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Mylabris OR Cantharides OR Agkistrodon OR Snake venom OR Bufonis Venenum OR</span></p>
<p style="top:762.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Bufo OR Bufo Siccus OR Toad venom OR Bufonis Crustum OR Toad cake OR Secretio</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:536.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 of 21</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Bufonis OR Hirudo OR Leech OR Scolopendra OR Scolopendrae OR Eupolyphaga OR</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Steleophaga OR Scorpio OR Gecko OR Tokay&#x201d; AND &#x201c;endometriosis&#x201d;. There were no</span></p>
<p style="top:122.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">language limitations in this study.</span></p>
<p style="top:145.0pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.3. Inclusion and Exclusion Criteria</span></i></p>
<p style="top:160.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Type of studies: Experimental studies, such as animal or cell studies, and clinical</span></p>
<p style="top:173.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">studies using toxic animal-based medicinal materials for treating endometriosis were</span></p>
<p style="top:185.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">included in this review. All types of clinical studies, including randomized controlled trials</span></p>
<p style="top:198.3pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(RCTs), observational studies, cohort studies, case reports, and case series were included in</span></p>
<p style="top:210.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">this review. Literature studies, qualitative studies, and surveys were excluded.</span></p>
<p style="top:223.3pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Subjects: Clinical studies with female patients with endometriosis were included. Ex-</span></p>
<p style="top:235.9pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">perimental studies on animal endometriosis models or cell culture studies were considered</span></p>
<p style="top:248.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">for inclusion.</span></p>
<p style="top:261.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Types of intervention: Studies using 10 types of toxic animal-based medicinal materials</span></p>
<p style="top:273.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in the treatment of endometriosis patients, endometriosis animal models, and endometrio-</span></p>
<p style="top:286.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">sis cells were included. In the case of toxic animal-based medicinal materials alone, a</span></p>
<p style="top:298.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">combination of toxic animal-based medicinal materials and other toxic medicinal materials</span></p>
<p style="top:311.2pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was also included.</span></p>
<p style="top:333.6pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.4. Study Selection and Data Extraction</span></i></p>
<p style="top:349.1pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Two independent authors (SIH and SHS) selected the studies according to the pre-</span></p>
<p style="top:361.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">de&#xfb01;ned criteria. Any disagreements were discussed by a third author (JKP). Two authors</span></p>
<p style="top:374.2pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(SIH, GTH) independently extracted the following data from the selected experimental</span></p>
<p style="top:386.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies: author, year, study design, toxic animal-based medicinal materials used in inter-</span></p>
<p style="top:399.3pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">vention, target cell (</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">)/animal model (</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">), dosage, treatment period, outcome</span></p>
<p style="top:411.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">measures, results, and components of herbal medicine. Two authors (SHS, YJY) indepen-</span></p>
<p style="top:424.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dently extracted the following data from clinical studies: author, study design, sample</span></p>
<p style="top:436.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">size, age, main symptoms, toxic animal-based medicinal materials used in intervention,</span></p>
<p style="top:449.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">control intervention, treatment duration, outcome measures, main results, adverse events,</span></p>
<p style="top:462.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">components of herbal medicine, dosage, frequency, and dosing period. We resolved any</span></p>
<p style="top:474.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">disagreements by discussing with a third author (JKP).</span></p>
<p style="top:497.1pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3. Results</span></b></p>
<p style="top:512.6pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">After literature searching, we identi&#xfb01;ed a total of 153 studies (6 in English database,</span></p>
<p style="top:525.2pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">146 in Chinese database, and 1 in Korean database), from which 74 duplicate studies were</span></p>
<p style="top:537.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">excluded. By screening the titles and abstracts of 79 studies, 11 studies were found to be</span></p>
<p style="top:550.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">irrelevant due to the study type (10 reviews and 1 survey), 25 studies irrelevant due to the</span></p>
<p style="top:562.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">subject, and 13 studies irrelevant due to the intervention were excluded. After assessing</span></p>
<p style="top:575.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the full text of the remaining 30 studies for eligibility, 20 studies were &#xfb01;nally included,</span></p>
<p style="top:587.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">excluding one study due to irrelevance in the study type, one study due to irrelevance in</span></p>
<p style="top:600.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the subject, three studies due to irrelevance in the intervention, and &#xfb01;ve studies due to</span></p>
<p style="top:613.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">insuf&#xfb01;cient details about the composition of the herbal medicine. Of the 20 studies &#xfb01;nally</span></p>
<p style="top:625.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">selected, 8 were experimental studies and 12 were clinical studies. A &#xfb02;ow diagram of the</span></p>
<p style="top:638.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">study selection process is shown in Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:536.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 of 21</span></p>
<p style="top:49.9pt;left:11.8pt;line-height:8.8pt"><i><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">Toxins </span></i><b><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">2021</span></b><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">, </span><i><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">13</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">, x FOR PEER REVIEW </span></p>
<p style="top:49.9pt;left:562.2pt;line-height:8.8pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt">4 of 24 </span></p>
<p style="top:57.2pt;left:11.8pt;line-height:8.8pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.8pt"> </span></p>
<p style="top:519.5pt;left:539.8pt;line-height:9.9pt"><b><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt"> </span></b></p>
<p style="top:542.7pt;left:35.2pt;line-height:9.9pt"><b><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">Figure 1. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">Flow chart of the study selection process. After literature searching, we identified a total of 153 studies, from </span></p>
<p style="top:555.4pt;left:35.2pt;line-height:9.9pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">which 74 duplicate studies were excluded. We screened </span><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">79 studies&#x2019; titles and abstracts. As a result, 49 studies were </span></p>
<p style="top:568.1pt;left:35.2pt;line-height:9.9pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">excluded, and 30 studies passed the first round of the selection process. Of these 30 studies, 10 irrelevant studies were </span></p>
<p style="top:580.7pt;left:35.2pt;line-height:9.9pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">excluded again, and the final 20 studies were selected for this study. Of the 20 studies finally selected, 8 were experimental </span></p>
<p style="top:593.4pt;left:35.2pt;line-height:9.9pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.9pt">studies and 12 were clinical studies.</span><span style="font-family:Arial,sans-serif;font-size:9.9pt"> </span></p>
<p style="top:619.5pt;left:155.3pt;line-height:11.0pt"><i><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">3.1. Preclinical Studies  </span></i></p>
<p style="top:636.9pt;left:178.7pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">Among the studies included in this analysis, there were eight preclinical studies [27</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">&#x2013;</span></p>
<p style="top:651.0pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">34] investigating the effect of animal toxins on endometriosis, two in vitro studies [28,30], </span></p>
<p style="top:665.2pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">one both in vivo and in vitro study [29], and five in vivo studies [27,31</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">34]. </span></p>
<p style="top:679.3pt;left:178.7pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">The medicinal interventions used in the eight studies were largely divided into three </span></p>
<p style="top:693.3pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">categories, namely medicinal compounds extracted from animal toxins in two studies </span></p>
<p style="top:707.4pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">[28,29], individual medicinal extracts in two studies [27,34], and medicinal decoctions in </span></p>
<p style="top:721.6pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">four studies [30</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">33]. The composition of the medicinal formulae used in the four studies </span></p>
<p style="top:735.7pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">is summarized in Table 1.  </span></p>
<p style="top:749.8pt;left:178.7pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">Among the toxic animal-based medical materials, Hirudo was the most commonly </span></p>
<p style="top:763.8pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">used in medicinal decoctions [30</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">33], followed by bufalin twice [28,29].  </span></p>
<p style="top:777.9pt;left:178.7pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">According to the eight studies, the underlying mechanisms of animal toxins against </span></p>
<p style="top:792.1pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">endometriosis were as follows: induction of apoptosis [28</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">30], inhibition of angiogenesis </span></p>
<p style="top:806.2pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">[31,32], reduction of estrogen level [27], suppression of matrix metalloproteinase (MMP)-</span></p>
<p style="top:820.3pt;left:155.3pt;line-height:11.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:11.0pt">9 expression [34], and anti-inflammatory effect [33] (Table 2).</span></p>
<img style="position:absolute;transform:matrix(.7521412,0,-0,.7508497,-25.958649,27.37268)" src="data:image/jpeg;base64,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">
<p style="top:533.8pt;left:57.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Flow chart of the study selection process. After literature searching, we identi&#xfb01;ed a total of 153 studies, from</span></p>
<p style="top:546.7pt;left:56.9pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">which 74 duplicate studies were excluded. We screened 79 studies&#x2019; titles and abstracts. As a result, 49 studies were excluded,</span></p>
<p style="top:559.5pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">and 30 studies passed the &#xfb01;rst round of the selection process. Of these 30 studies, 10 irrelevant studies were excluded again,</span></p>
<p style="top:572.3pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and the &#xfb01;nal 20 studies were selected for this study. Of the 20 studies &#xfb01;nally selected, 8 were experimental studies and 12</span></p>
<p style="top:585.1pt;left:56.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">were clinical studies.</span></p>
<p style="top:608.6pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1. Preclinical Studies</span></i></p>
<p style="top:624.2pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Among the studies included in this analysis, there were eight preclinical studies</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span></p>
<p style="top:636.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">investigating the effect of animal toxins on endometriosis, two</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], one</span></p>
<p style="top:649.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">both in vivo and in vitro study [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], and &#xfb01;ve in vivo studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:661.7pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The medicinal interventions used in the eight studies were largely divided into</span></p>
<p style="top:674.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">three categories, namely medicinal compounds extracted from animal toxins in two stud-</span></p>
<p style="top:686.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ies</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, individual medicinal extracts in two studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], and medicinal decoctions</span></p>
<p style="top:699.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in four studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The composition of the medicinal formulae used in the four studies</span></p>
<p style="top:712.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">is summarized in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:536.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5 of 21</span></p>
<p style="top:97.3pt;left:127.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Composition of the herbal medicines used in the included preclinical studies.</span></p>
<p style="top:118.4pt;left:47.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">First Author</span></b></p>
<p style="top:129.3pt;left:60.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(Year)</span></b></p>
<p style="top:123.9pt;left:147.7pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Herbal Medicine</span></b></p>
<p style="top:123.9pt;left:383.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Component</span></b></p>
<p style="top:150.6pt;left:66.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liu</span></p>
<p style="top:161.5pt;left:52.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(2014) [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:156.0pt;left:138.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pingchongjiangnifang</span></p>
<p style="top:145.1pt;left:265.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cinnamomi Ramulus 15 g, Draconis Sanguis 3 g, Trogopterorum Faeces</span></p>
<p style="top:156.0pt;left:264.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10 g, Typhae Pollen 6 g, Aquilariae Lignum 6 g, Hirudo 3 g, Liriopis seu</span></p>
<p style="top:167.0pt;left:285.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ophiopogonis Tuber 10 g, Glycyrrhizae Radix et Rhizoma 6 g</span></p>
<p style="top:183.4pt;left:67.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Xu</span></p>
<p style="top:194.4pt;left:52.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(2018) [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:188.9pt;left:153.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Eleng Capsule</span></p>
<p style="top:178.0pt;left:265.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Curcumae Rhizoma 10 g, Sparganii Rhizoma 10 g, Salviae Miltiorrhizae</span></p>
<p style="top:188.9pt;left:264.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Radix 15 g, Curcumae Radix 15 g, Paeoniae Radix Rubra 15 g, Pelodiscis</span></p>
<p style="top:199.9pt;left:357.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Carapax 15 g, Hirudo 3 g</span></p>
<p style="top:210.8pt;left:66.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liu</span></p>
<p style="top:221.8pt;left:52.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(2020) [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:216.3pt;left:133.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Huangzhi Neiyi Capsule</span></p>
<p style="top:216.3pt;left:289.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hirudo 3 g, Rhei Radix et Rhizoma 9 g, Cyperi Rhizoma 6 g</span></p>
<p style="top:238.2pt;left:61.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wang</span></p>
<p style="top:249.2pt;left:52.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(2005) [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:243.7pt;left:117.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wudan Wan Modi&#xfb01;ed Decoction</span></p>
<p style="top:232.8pt;left:265.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Salviae Miltiorrhizae Radix 10 g, Paeoniae Radix Rubra 10 g, Curcumae</span></p>
<p style="top:243.7pt;left:262.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rhizoma 10 g, Cinnamomi Cortex 6 g, Corydalis Tuber 10 g, Hirudo 10 g,</span></p>
<p style="top:254.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Scolopendra two pieces, Pelodiscis Carapax 15 g, Sappan Lignum 10 g</span></p>
<p style="top:284.1pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Among the toxic animal-based medical materials, Hirudo was the most commonly</span></p>
<p style="top:296.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">used in medicinal decoctions [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], followed by bufalin twice [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:309.3pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">According to the eight studies, the underlying mechanisms of animal toxins against</span></p>
<p style="top:321.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">endometriosis were as follows: induction of apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], inhibition of angiogen-</span></p>
<p style="top:334.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">esis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], reduction of estrogen level [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], suppression of matrix metalloproteinase</span></p>
<p style="top:347.0pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(MMP)-9 expression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], and anti-in&#xfb02;ammatory effect [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] (Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">).</span></p>
<p style="top:369.4pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2. Clinical Studies</span></i></p>
<p style="top:384.8pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In this analysis, we included a total of 12 clinical studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] examining the</span></p>
<p style="top:397.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">therapeutic effects of herbal medicine containing animal toxins on endometriosis, of which</span></p>
<p style="top:410.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#xfb01;ve were case series [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and seven were randomized controlled trials (RCTs) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:422.5pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">According to these studies, dysmenorrhea was the most common symptom in patients</span></p>
<p style="top:435.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">diagnosed with endometriosis, followed by infertility, pelvic mass, dyspareunia, pelvic</span></p>
<p style="top:447.7pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pain, mittelschmerz, and anal pain.</span></p>
<p style="top:460.2pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In all the clinical studies, medicinal decoctions were used. Quyu Jiedu Xiaozheng</span></p>
<p style="top:472.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Decoction was used in two studies, but at different doses [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Other than that, differ-</span></p>
<p style="top:485.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ent prescriptions were used in the remaining studies. The toxic animal-based medicinal</span></p>
<p style="top:497.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">materials used in these studies include Hirudo, Scolopendra, Eupolyphaga, and Scor-</span></p>
<p style="top:510.4pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pio. Hirudo was used in a total of eight studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] at daily doses of</span></p>
<p style="top:522.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">0.5 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], 1&#x2013;2 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], 4&#x2013;5 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], 6 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], 9 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and 10 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Scolopendra was used</span></p>
<p style="top:535.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in &#xfb01;ve studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] at varying doses of 0.5 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], one to two pieces [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], two</span></p>
<p style="top:548.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pieces</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, and 6 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] per day. Eupolyphaga was used in four studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] at</span></p>
<p style="top:560.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">doses of 6 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], 10 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and 12 g [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] per day. Scorpio was used in one study [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]</span></p>
<p style="top:573.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">at a dose of 6 g per day. The administration duration varied from 1 to 9 months, with</span></p>
<p style="top:585.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">3 months [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] being the most common. The timing of administration also varied;</span></p>
<p style="top:598.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">some decoctions were discontinued during the menstrual period [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], administered</span></p>
<p style="top:610.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">throughout the menstrual cycle [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], or administered after menstruation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:623.5pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">All included clinical studies reported improvement of symptoms related to endometrio-</span></p>
<p style="top:635.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">sis, and three studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] reported that no side effects were observed (Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">). The</span></p>
<p style="top:648.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">dosing regimens of herbal medicines containing toxic animal-based medicinal materials in</span></p>
<p style="top:661.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the included clinical studies are presented in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:783.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 of 21</span></p>
<p style="top:84.7pt;left:305.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Characteristics of the included preclinical studies.</span></p>
<p style="top:110.3pt;left:46.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:119.7pt;left:52.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ID</span></b></p>
<p style="top:110.3pt;left:86.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:119.7pt;left:88.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:110.3pt;left:131.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:119.7pt;left:128.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Design</span></b></p>
<p style="top:105.5pt;left:189.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal Medicine</span></b></p>
<p style="top:115.0pt;left:182.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Toxic Animal-Based</span></b></p>
<p style="top:124.5pt;left:182.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medicinal Materials)</span></b></p>
<p style="top:105.5pt;left:313.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Target Cells</span></b></p>
<p style="top:115.0pt;left:289.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(In Vitro)/Animal Model</span></b></p>
<p style="top:124.5pt;left:318.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(In Vivo)</span></b></p>
<p style="top:115.0pt;left:406.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosage</span></b></p>
<p style="top:110.3pt;left:458.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Treatment</span></b></p>
<p style="top:119.7pt;left:464.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Period</span></b></p>
<p style="top:115.0pt;left:545.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Outcome Measures</span></b></p>
<p style="top:115.0pt;left:717.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Results</span></b></p>
<p style="top:162.4pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1</span></p>
<p style="top:152.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Lee</span></p>
<p style="top:162.4pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2006)</span></p>
<p style="top:171.9pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:162.4pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:162.4pt;left:191.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bee venom (n.s.)</span></p>
<p style="top:157.7pt;left:308.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female SD rats</span></p>
<p style="top:167.2pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(autotransplantation method)</span></p>
<p style="top:152.9pt;left:400.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0.1 mg/mL</span></p>
<p style="top:162.4pt;left:406.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(0.1 mL,</span></p>
<p style="top:171.9pt;left:411.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CV4)</span></p>
<p style="top:157.7pt;left:462.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 weeks</span></p>
<p style="top:167.2pt;left:454.2pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(3 times/week)</span></p>
<p style="top:143.5pt;left:527.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Histological analysis (H&amp;E)</span></p>
<p style="top:152.9pt;left:540.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Serum progesterone</span></p>
<p style="top:162.4pt;left:548.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Serum estradiol</span></p>
<p style="top:171.9pt;left:517.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Serum cytokines (TNF-</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, IL-2, -4,</span></p>
<p style="top:181.3pt;left:567.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-6, -10)</span></p>
<p style="top:138.8pt;left:661.5pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">1) Inhibited proliferation of endometrial</span></p>
<p style="top:148.2pt;left:720.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">tissue</span></p>
<p style="top:157.7pt;left:717.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) NSD</span></p>
<p style="top:167.1pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:176.6pt;left:664.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) TNF-</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, IL-4, NSDIL-2: Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:186.1pt;left:690.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">IL-6, IL-10: Increased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:242.9pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2</span></p>
<p style="top:233.4pt;left:90.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nasu</span></p>
<p style="top:242.9pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2005)</span></p>
<p style="top:252.4pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:242.9pt;left:128.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:238.2pt;left:207.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bufalin</span></p>
<p style="top:247.6pt;left:186.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Bufonis Venenum)</span></p>
<p style="top:242.9pt;left:289.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Human endometrial cells</span></p>
<p style="top:233.5pt;left:397.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0, 0.001, 0.01,</span></p>
<p style="top:242.9pt;left:410.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0.1, 1,</span></p>
<p style="top:252.4pt;left:402.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 ng/mL</span></p>
<p style="top:242.9pt;left:475.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:224.0pt;left:515.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Cell proliferation and cell viability</span></p>
<p style="top:233.4pt;left:544.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Apoptotic cells(%)</span></p>
<p style="top:242.9pt;left:519.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Cell cycle assay(&#xfb02;ow cytometry)</span></p>
<p style="top:252.4pt;left:514.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Apoptosis-related proteins and cell</span></p>
<p style="top:261.8pt;left:542.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">cycle-related proteins</span></p>
<p style="top:200.3pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">e</span></sup></p>
<p style="top:209.8pt;left:706.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Increased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup></p>
<p style="top:219.2pt;left:666.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) G0/G1 cell cycle arrest observed</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">c</span></sup></p>
<p style="top:228.7pt;left:670.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Downregulated(Cyclin A, Bcl-2,</span></p>
<p style="top:238.2pt;left:701.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bcl-XL proteins),</span></p>
<p style="top:247.6pt;left:676.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Upregulated(Bax, p21, cleaved</span></p>
<p style="top:257.1pt;left:698.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">caspase-9 protein),</span></p>
<p style="top:266.6pt;left:667.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Unchanged(Cyclin B, cyclin D3, Fas,</span></p>
<p style="top:276.0pt;left:664.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Fas ligand, cleaved caspase-3, cleaved</span></p>
<p style="top:285.5pt;left:698.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">caspase-8 protein)</span></p>
<p style="top:374.4pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3</span></p>
<p style="top:364.5pt;left:92.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cho</span></p>
<p style="top:374.0pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2018)</span></p>
<p style="top:383.5pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:331.3pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:366.3pt;left:207.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bufalin</span></p>
<p style="top:375.8pt;left:186.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Bufonis Venenum)</span></p>
<p style="top:326.8pt;left:295.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female C57BL/6 mice</span></p>
<p style="top:336.3pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(Autotransplantation method)</span></p>
<p style="top:331.3pt;left:404.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1 mg/kg</span></p>
<p style="top:331.3pt;left:463.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">21 days</span></p>
<p style="top:309.7pt;left:519.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Volume of endometriotic lesions</span></p>
<p style="top:319.2pt;left:514.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Protein levels of the SRC-1 isoform</span></p>
<p style="top:328.7pt;left:539.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Protein levels of ER</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b2;</span></p>
<p style="top:305.0pt;left:705.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:314.5pt;left:706.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Increased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:324.0pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:413.8pt;left:128.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:404.8pt;left:321.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Human</span></p>
<p style="top:414.3pt;left:313.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">endometrial</span></p>
<p style="top:423.8pt;left:326.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">cells</span></p>
<p style="top:404.8pt;left:399.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0, 10, 20, 50,</span></p>
<p style="top:414.3pt;left:397.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">100, 200, 400,</span></p>
<p style="top:423.8pt;left:406.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">800 nM</span></p>
<p style="top:413.8pt;left:475.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:364.1pt;left:515.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Intrinsic transcriptional activity of</span></p>
<p style="top:373.5pt;left:548.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">the SRC-1 isoform</span></p>
<p style="top:383.0pt;left:515.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Intrinsic transcriptional activity of</span></p>
<p style="top:392.5pt;left:538.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ER</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Levels of PSMD2</span></p>
<p style="top:401.9pt;left:549.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Levels of Ki-67</span></p>
<p style="top:411.4pt;left:531.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5) Levels of active caspase 3</span></p>
<p style="top:420.9pt;left:538.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6) Levels of active IL-1</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b2;</span></p>
<p style="top:430.3pt;left:543.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7) Levels of caspase 1</span></p>
<p style="top:439.8pt;left:515.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8) Levels of ER-stress markers(PERK,</span></p>
<p style="top:449.3pt;left:556.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">PDI, and BiP)</span></p>
<p style="top:358.6pt;left:706.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Increased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:368.1pt;left:717.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) NSD</span></p>
<p style="top:377.6pt;left:666.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Increased (epithelium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:387.0pt;left:690.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Decreased (stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">c</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:396.5pt;left:684.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5) Increased (epithelium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:407.0pt;left:691.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6) Increased (stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:416.4pt;left:691.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7) Increased (stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">c</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:425.9pt;left:672.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8) PERK: Increased (epithelium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span></p>
<p style="top:436.4pt;left:713.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">),</span></p>
<p style="top:445.8pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">PDI: Increased (epithelium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">c</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">d</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">),</span></p>
<p style="top:455.3pt;left:663.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">BiP: Increased (epithelium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">c</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, stroma</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:488.5pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4</span></p>
<p style="top:479.0pt;left:93.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Liu</span></p>
<p style="top:488.5pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2014)</span></p>
<p style="top:497.9pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:488.5pt;left:128.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:488.5pt;left:169.0pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Pingchongjiangnifang(Hirudo)</span></p>
<p style="top:488.5pt;left:289.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Human endometrial cells</span></p>
<p style="top:469.5pt;left:404.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5%, 10%,</span></p>
<p style="top:479.0pt;left:398.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15%, 20% of</span></p>
<p style="top:488.5pt;left:400.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">the drug in</span></p>
<p style="top:497.9pt;left:409.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">serum</span></p>
<p style="top:507.4pt;left:408.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(1 mL)</span></p>
<p style="top:488.5pt;left:475.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:474.3pt;left:545.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Cell proliferation</span></p>
<p style="top:483.7pt;left:531.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Number of adherent cells</span></p>
<p style="top:493.2pt;left:531.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Number of invading cells</span></p>
<p style="top:502.7pt;left:550.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Apoptosis rate</span></p>
<p style="top:474.3pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:483.7pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:493.2pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:502.7pt;left:705.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:783.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7 of 21</span></p>
<p style="top:94.5pt;left:393.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:120.0pt;left:46.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:52.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ID</span></b></p>
<p style="top:120.0pt;left:86.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:129.5pt;left:88.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:120.0pt;left:131.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:128.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Design</span></b></p>
<p style="top:115.3pt;left:189.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal Medicine</span></b></p>
<p style="top:124.8pt;left:182.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Toxic Animal-Based</span></b></p>
<p style="top:134.2pt;left:182.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medicinal Materials)</span></b></p>
<p style="top:115.3pt;left:313.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Target Cells</span></b></p>
<p style="top:124.8pt;left:289.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(In Vitro)/Animal Model</span></b></p>
<p style="top:134.2pt;left:318.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(In Vivo)</span></b></p>
<p style="top:124.8pt;left:406.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosage</span></b></p>
<p style="top:120.0pt;left:458.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Treatment</span></b></p>
<p style="top:129.5pt;left:464.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Period</span></b></p>
<p style="top:124.8pt;left:545.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Outcome Measures</span></b></p>
<p style="top:124.8pt;left:717.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Results</span></b></p>
<p style="top:200.3pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5</span></p>
<p style="top:190.8pt;left:94.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Xu</span></p>
<p style="top:200.3pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2018)</span></p>
<p style="top:209.8pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:200.3pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:200.3pt;left:179.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Eleng Capsule(Hirudo)</span></p>
<p style="top:195.6pt;left:308.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female SD rats</span></p>
<p style="top:205.1pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(autotransplantation method)</span></p>
<p style="top:171.9pt;left:408.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 g/kg</span></p>
<p style="top:181.4pt;left:399.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(high dose),</span></p>
<p style="top:190.8pt;left:408.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 g/kg</span></p>
<p style="top:200.3pt;left:403.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(medium</span></p>
<p style="top:209.8pt;left:410.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dose),</span></p>
<p style="top:219.2pt;left:407.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1 g/kg</span></p>
<p style="top:228.7pt;left:401.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low dose)</span></p>
<p style="top:200.3pt;left:463.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28 days</span></p>
<p style="top:157.7pt;left:524.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Volume of endometriotic foci</span></p>
<p style="top:167.2pt;left:527.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Histological analysis (H&amp;E)</span></p>
<p style="top:176.6pt;left:537.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Serum levels of VEGF</span></p>
<p style="top:186.1pt;left:538.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Serum levels of bFGF</span></p>
<p style="top:195.6pt;left:537.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5) Serum levels of PDGF</span></p>
<p style="top:205.0pt;left:540.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6) Expression of VEGF</span></p>
<p style="top:214.5pt;left:541.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7) Expression of bFGF</span></p>
<p style="top:224.0pt;left:540.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8) Expression of PDGF</span></p>
<p style="top:233.4pt;left:539.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9) Expression of NF-</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">B</span></p>
<p style="top:242.9pt;left:539.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10) Expression of TLR4</span></p>
<p style="top:148.5pt;left:662.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:157.9pt;left:708.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Improved</span></p>
<p style="top:168.4pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:178.9pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:189.3pt;left:662.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:199.8pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:210.3pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:220.7pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:231.2pt;left:661.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:241.6pt;left:675.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/medium</span></p>
<p style="top:250.8pt;left:715.5pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> b</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:286.3pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6</span></p>
<p style="top:276.8pt;left:93.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Liu</span></p>
<p style="top:286.3pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2020)</span></p>
<p style="top:295.8pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:286.3pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:281.6pt;left:176.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Huangzhi Neiyi Capsule</span></p>
<p style="top:291.0pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Hirudo)</span></p>
<p style="top:281.6pt;left:308.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female SD rats</span></p>
<p style="top:291.1pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(autotransplantation method)</span></p>
<p style="top:272.1pt;left:408.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 g/kg</span></p>
<p style="top:281.6pt;left:399.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(high dose),</span></p>
<p style="top:291.0pt;left:405.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4.5 g/kg</span></p>
<p style="top:300.5pt;left:401.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low dose)</span></p>
<p style="top:286.3pt;left:463.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28 days</span></p>
<p style="top:267.4pt;left:564.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) PCNA</span></p>
<p style="top:276.8pt;left:566.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) CD31</span></p>
<p style="top:286.3pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) VEGF in peritoneal &#xfb02;uid</span></p>
<p style="top:295.8pt;left:527.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) mRNA expression of VEGF</span></p>
<p style="top:305.2pt;left:525.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5) mRNA expression of HIF-1</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span></p>
<p style="top:266.4pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:275.8pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:285.3pt;left:682.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:295.8pt;left:681.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">),</span></p>
<p style="top:306.2pt;left:681.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4) Decreased (high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/low</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:353.6pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7</span></p>
<p style="top:344.1pt;left:89.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Wang</span></p>
<p style="top:353.6pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2005)</span></p>
<p style="top:363.1pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:353.6pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:344.1pt;left:181.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Wudan Wan Modi&#xfb01;ed</span></p>
<p style="top:353.6pt;left:202.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Decoction</span></p>
<p style="top:363.1pt;left:180.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Hirudo, Scolopendra)</span></p>
<p style="top:348.9pt;left:308.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female SD rats</span></p>
<p style="top:358.4pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(autotransplantation method)</span></p>
<p style="top:320.5pt;left:399.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1 mL/100 g</span></p>
<p style="top:330.0pt;left:398.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(26.56 g/kg)</span></p>
<p style="top:339.4pt;left:399.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(high dose),</span></p>
<p style="top:348.9pt;left:399.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1/2 diluted</span></p>
<p style="top:358.3pt;left:403.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(medium</span></p>
<p style="top:367.8pt;left:410.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dose),</span></p>
<p style="top:377.3pt;left:399.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1/4 diluted</span></p>
<p style="top:386.7pt;left:401.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low dose)</span></p>
<p style="top:353.6pt;left:463.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28 days</span></p>
<p style="top:339.4pt;left:517.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER for disappearance of ectopic</span></p>
<p style="top:348.9pt;left:571.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">cysts</span></p>
<p style="top:358.3pt;left:514.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Effects on abdominal in&#xfb02;ammation</span></p>
<p style="top:367.8pt;left:511.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) TER for ectopic endometrial atrophy</span></p>
<p style="top:330.0pt;left:663.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Improved (medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">), NSD</span></p>
<p style="top:339.4pt;left:721.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low)</span></p>
<p style="top:348.9pt;left:661.5pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">2) Less severe adhesion (medium/high),</span></p>
<p style="top:358.3pt;left:682.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">More severe adhesion (low)</span></p>
<p style="top:367.8pt;left:663.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Improved (medium</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/high</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">), NSD</span></p>
<p style="top:377.3pt;left:721.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low)</span></p>
<p style="top:425.6pt;left:55.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8</span></p>
<p style="top:415.7pt;left:88.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Zhang</span></p>
<p style="top:425.2pt;left:89.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2015)</span></p>
<p style="top:434.6pt;left:92.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:415.2pt;left:129.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:415.4pt;left:171.9pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Gloydius brevicaudus</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> venom</span></p>
<p style="top:424.8pt;left:194.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Snake venom)</span></p>
<p style="top:410.5pt;left:308.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Female SD rats</span></p>
<p style="top:420.0pt;left:283.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(autotransplantation method)</span></p>
<p style="top:401.0pt;left:399.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0.75 mg/kg</span></p>
<p style="top:410.5pt;left:400.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(low dose),</span></p>
<p style="top:419.9pt;left:401.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1.5 mg/kg</span></p>
<p style="top:429.4pt;left:400.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(high dose)</span></p>
<p style="top:415.2pt;left:462.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 weeks</span></p>
<p style="top:410.5pt;left:537.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Volume of ectopic foci</span></p>
<p style="top:419.9pt;left:538.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Expression of MMP-9</span></p>
<p style="top:410.5pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:419.9pt;left:705.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:443.6pt;left:128.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:443.6pt;left:284.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rat ectopic endometrial cells</span></p>
<p style="top:438.9pt;left:400.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Disintegrin</span></p>
<p style="top:448.3pt;left:400.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1.5</span><span style="font-family:EURM10,serif;font-size:8.0pt"> &#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">g/mL</span></p>
<p style="top:443.6pt;left:475.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:443.6pt;left:538.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Expression of MMP-9</span></p>
<p style="top:443.9pt;left:705.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Decreased</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:461.7pt;left:57.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> &lt; 0.05;</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> b</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> &lt; 0.01;</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> c</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> &lt; 0.001;</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> d</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> &lt; 0.0001. SD rats: Sprague&#x2013;Dawley rats; n.s.: not stated; n.r.: not reported; TER: total effectiveness rate; mo: month; NSD: no signi&#xfb01;cant difference; SRC-1: steroid receptor</span></p>
<p style="top:472.4pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">coactivator-1; ER</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">: estrogen receptor beta; PSMD2: proteasome 26S subunit, non-ATPase 2; IL: interleukin; PERK: protein kinase RNA-like endoplasmic reticulum kinase; PDI: protein disul&#xfb01;de isomerase;</span></p>
<p style="top:481.9pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">BiP: binding immunoglobulin protein; H&amp;E: hematoxylin and eosin staining; MMP-9: matrix metallopeptidase-9; VEGF: vascular endothelial growth factor; bFGF: basic &#xfb01;broblast growth factor; PDGF:</span></p>
<p style="top:491.4pt;left:57.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">platelet-derived growth factor; NF-</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">B: nuclear factor kappa-light-chain-enhancer of activated B cells; TLR4: toll-like receptor 4; PCNA: proliferating cell nuclear antigen; CD31: cluster of differentiation 31;</span></p>
<p style="top:500.9pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">HIF-1</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">: hypoxia-inducible factor 1-alpha.</span></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:783.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8 of 21</span></p>
<p style="top:94.5pt;left:311.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 3.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Characteristics of the included clinical studies.</span></p>
<p style="top:120.0pt;left:42.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:46.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ID</span></b></p>
<p style="top:120.0pt;left:72.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:129.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:120.0pt;left:108.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:106.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Design</span></b></p>
<p style="top:115.3pt;left:150.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sample</span></b></p>
<p style="top:124.8pt;left:156.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Size</span></b></p>
<p style="top:134.2pt;left:147.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(TG/CG)</span></b></p>
<p style="top:115.3pt;left:205.7pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Mean</span></b></p>
<p style="top:124.8pt;left:197.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Age</span></b><i><span style="font-family:CMSY10,serif;font-size:8.3pt"> &#xb1;</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> SD</span></b></p>
<p style="top:134.2pt;left:195.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Min, Max)</span></b></p>
<p style="top:124.8pt;left:259.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Main Symptoms</span></b></p>
<p style="top:124.8pt;left:343.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Diagnostic Criteria</span></b></p>
<p style="top:124.8pt;left:428.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Intervention</span></b></p>
<p style="top:120.0pt;left:496.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Control</span></b></p>
<p style="top:129.5pt;left:487.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Intervention</span></b></p>
<p style="top:120.0pt;left:551.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Treatment</span></b></p>
<p style="top:129.5pt;left:557.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Period</span></b></p>
<p style="top:124.8pt;left:608.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Outcome Measures</span></b></p>
<p style="top:124.8pt;left:707.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Main Results</span></b></p>
<p style="top:124.8pt;left:785.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">AE</span></b></p>
<p style="top:157.9pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1</span></p>
<p style="top:148.5pt;left:75.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Wu</span></p>
<p style="top:158.0pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(1993)</span></p>
<p style="top:167.4pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:153.2pt;left:110.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Case</span></p>
<p style="top:162.7pt;left:109.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">series</span></p>
<p style="top:157.9pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">60</span></p>
<p style="top:153.2pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:162.7pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(20,48)</span></p>
<p style="top:148.5pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:157.9pt;left:273.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">infertility,</span></p>
<p style="top:167.4pt;left:256.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstrual disorder</span></p>
<p style="top:148.5pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:157.9pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:167.4pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:153.2pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:162.7pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:157.9pt;left:509.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:157.9pt;left:564.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:157.9pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:157.9pt;left:719.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">91.67%</span></p>
<p style="top:157.9pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:191.1pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2</span></p>
<p style="top:181.7pt;left:72.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Zhang</span></p>
<p style="top:191.2pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2007)</span></p>
<p style="top:200.6pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:186.4pt;left:110.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Case</span></p>
<p style="top:195.9pt;left:109.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">series</span></p>
<p style="top:191.1pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">30</span></p>
<p style="top:186.4pt;left:212.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">32</span></p>
<p style="top:195.9pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(23,43)</span></p>
<p style="top:181.7pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:191.1pt;left:264.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">mittelschmerz,</span></p>
<p style="top:200.6pt;left:263.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">endometrioma</span></p>
<p style="top:181.7pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:191.1pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:200.6pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:186.4pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:195.9pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:191.1pt;left:509.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:191.1pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:191.1pt;left:635.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">VAS</span></p>
<p style="top:191.1pt;left:715.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Positive</span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:191.1pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:233.8pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3</span></p>
<p style="top:224.3pt;left:76.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Xu</span></p>
<p style="top:233.9pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2007)</span></p>
<p style="top:243.3pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:229.1pt;left:110.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Case</span></p>
<p style="top:238.5pt;left:109.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">series</span></p>
<p style="top:233.8pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">52</span></p>
<p style="top:229.1pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:238.5pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(23,46)</span></p>
<p style="top:214.9pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:224.4pt;left:251.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">pelvic pain, anal pain,</span></p>
<p style="top:233.8pt;left:267.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dyspareunia,</span></p>
<p style="top:243.3pt;left:255.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstrual disorder,</span></p>
<p style="top:252.7pt;left:273.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">infertility</span></p>
<p style="top:224.3pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:233.8pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:243.3pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:229.1pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:238.5pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:233.8pt;left:509.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:233.8pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:233.8pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:233.8pt;left:719.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">88.46%</span></p>
<p style="top:233.8pt;left:782.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">none</span></p>
<p style="top:290.7pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4</span></p>
<p style="top:281.3pt;left:72.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Zhang</span></p>
<p style="top:290.7pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2007)</span></p>
<p style="top:300.1pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:285.9pt;left:110.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Case</span></p>
<p style="top:295.4pt;left:109.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">series</span></p>
<p style="top:290.7pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">78</span></p>
<p style="top:285.9pt;left:209.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">34.5</span></p>
<p style="top:295.4pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(21,46)</span></p>
<p style="top:281.2pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:290.7pt;left:268.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">pelvic mass,</span></p>
<p style="top:300.1pt;left:273.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">infertility</span></p>
<p style="top:281.2pt;left:341.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Gynecological exam,</span></p>
<p style="top:290.7pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography,</span></p>
<p style="top:300.1pt;left:356.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">laparoscopy</span></p>
<p style="top:285.9pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:295.4pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:290.7pt;left:509.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:290.7pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:267.0pt;left:625.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER for</span></p>
<p style="top:276.5pt;left:617.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dysmenorrhea</span></p>
<p style="top:285.9pt;left:613.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) TER for pelvic</span></p>
<p style="top:295.4pt;left:634.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">mass</span></p>
<p style="top:304.9pt;left:612.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Pregnancy rate</span></p>
<p style="top:314.3pt;left:615.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(within 2 years)</span></p>
<p style="top:281.2pt;left:715.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) 94.11%</span></p>
<p style="top:290.7pt;left:717.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) 87.5%</span></p>
<p style="top:300.1pt;left:714.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) 19.05%</span></p>
<p style="top:290.7pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:342.8pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5</span></p>
<p style="top:333.3pt;left:73.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Feng</span></p>
<p style="top:342.8pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2014)</span></p>
<p style="top:352.2pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:338.1pt;left:110.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Case</span></p>
<p style="top:347.5pt;left:109.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">series</span></p>
<p style="top:342.8pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">35</span></p>
<p style="top:338.1pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:347.5pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(23,42)</span></p>
<p style="top:342.8pt;left:273.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Infertility</span></p>
<p style="top:333.3pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:342.8pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:352.2pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:338.1pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:347.5pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:342.8pt;left:509.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">-</span></p>
<p style="top:342.8pt;left:557.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1&#x2013;6 mo</span></p>
<p style="top:328.6pt;left:606.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER for pregnancy</span></p>
<p style="top:338.1pt;left:616.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Spontaneous</span></p>
<p style="top:347.5pt;left:606.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">abortion rate in early</span></p>
<p style="top:357.0pt;left:624.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">pregnancy</span></p>
<p style="top:338.1pt;left:715.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) 82.86%</span></p>
<p style="top:347.5pt;left:714.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) 17.14%</span></p>
<p style="top:342.8pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:385.7pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6</span></p>
<p style="top:376.3pt;left:74.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Han</span></p>
<p style="top:385.8pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2009)</span></p>
<p style="top:395.2pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:385.7pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:381.0pt;left:158.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">156</span></p>
<p style="top:390.5pt;left:150.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(78/78)</span></p>
<p style="top:381.0pt;left:209.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28.5</span></p>
<p style="top:390.5pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(18,48)</span></p>
<p style="top:385.7pt;left:284.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:381.0pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:390.5pt;left:356.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">laparoscopy</span></p>
<p style="top:381.0pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:390.5pt;left:429.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(A)</span></p>
<p style="top:381.0pt;left:498.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:390.5pt;left:489.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(B)</span></p>
<p style="top:385.7pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 mo</span></p>
<p style="top:376.3pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:385.7pt;left:612.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Pregnancy rate</span></p>
<p style="top:395.2pt;left:611.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Recurrence rate</span></p>
<p style="top:371.8pt;left:710.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:381.3pt;left:701.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) 11.53%(TG) vs</span></p>
<p style="top:390.8pt;left:718.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0%(CG)</span></p>
<p style="top:400.2pt;left:710.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:385.7pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:438.2pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7</span></p>
<p style="top:428.8pt;left:72.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Zhang</span></p>
<p style="top:438.2pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2009)</span></p>
<p style="top:447.6pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:438.2pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:433.4pt;left:158.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">128</span></p>
<p style="top:443.0pt;left:147.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(45/43/40)</span></p>
<p style="top:433.4pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:442.9pt;left:207.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(n.r.)</span></p>
<p style="top:433.4pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:442.9pt;left:269.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">pelvic mass</span></p>
<p style="top:414.5pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:424.0pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:433.4pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography,</span></p>
<p style="top:442.9pt;left:356.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">laparoscopy,</span></p>
<p style="top:452.4pt;left:349.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">antiendometrial</span></p>
<p style="top:461.8pt;left:348.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">antibody, CA125</span></p>
<p style="top:433.4pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:442.9pt;left:429.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(A)</span></p>
<p style="top:424.0pt;left:488.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CG1: Herbal</span></p>
<p style="top:433.4pt;left:489.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(B)</span></p>
<p style="top:442.9pt;left:488.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CG2: Herbal</span></p>
<p style="top:452.4pt;left:488.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(C)</span></p>
<p style="top:438.2pt;left:557.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3&#x2013;6 mo</span></p>
<p style="top:424.0pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:433.4pt;left:612.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Dysmenorrhea</span></p>
<p style="top:442.9pt;left:634.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">score</span></p>
<p style="top:452.4pt;left:608.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Pelvic mass score</span></p>
<p style="top:414.5pt;left:695.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Positive (vs CG1</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:424.0pt;left:717.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/CG2</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:433.4pt;left:695.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Positive (vs CG1</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:442.9pt;left:716.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/CG2</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:452.4pt;left:695.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Positive (vs CG1</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:461.8pt;left:716.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">/CG2</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.0pt">)</span></p>
<p style="top:438.2pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:490.3pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8</span></p>
<p style="top:480.8pt;left:75.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Lin</span></p>
<p style="top:490.3pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2011)</span></p>
<p style="top:499.7pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:490.3pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:485.6pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">70</span></p>
<p style="top:495.0pt;left:150.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(40/30)</span></p>
<p style="top:485.6pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:495.0pt;left:207.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(n.r.)</span></p>
<p style="top:490.3pt;left:263.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea</span></p>
<p style="top:480.8pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:490.3pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography,</span></p>
<p style="top:499.7pt;left:365.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CA125</span></p>
<p style="top:485.6pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:495.0pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:490.3pt;left:487.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Mifepristone</span></p>
<p style="top:490.3pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 mo</span></p>
<p style="top:476.1pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:485.6pt;left:625.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) TER for</span></p>
<p style="top:495.0pt;left:617.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dysmenorrhea</span></p>
<p style="top:504.5pt;left:627.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) CA125</span></p>
<p style="top:480.8pt;left:718.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) NSD</span></p>
<p style="top:490.3pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:499.7pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:490.3pt;left:782.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">none</span></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:783.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 of 21</span></p>
<p style="top:94.5pt;left:393.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 3.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:120.0pt;left:42.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:46.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ID</span></b></p>
<p style="top:120.0pt;left:72.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:129.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:120.0pt;left:108.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:129.5pt;left:106.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Design</span></b></p>
<p style="top:115.3pt;left:150.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sample</span></b></p>
<p style="top:124.8pt;left:156.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Size</span></b></p>
<p style="top:134.2pt;left:147.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(TG/CG)</span></b></p>
<p style="top:115.3pt;left:205.7pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Mean</span></b></p>
<p style="top:124.8pt;left:197.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Age</span></b><i><span style="font-family:CMSY10,serif;font-size:8.3pt"> &#xb1;</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> SD</span></b></p>
<p style="top:134.2pt;left:195.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Min, Max)</span></b></p>
<p style="top:124.8pt;left:259.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Main Symptoms</span></b></p>
<p style="top:124.8pt;left:343.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Diagnostic Criteria</span></b></p>
<p style="top:124.8pt;left:428.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Intervention</span></b></p>
<p style="top:120.0pt;left:496.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Control</span></b></p>
<p style="top:129.5pt;left:487.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Intervention</span></b></p>
<p style="top:120.0pt;left:551.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Treatment</span></b></p>
<p style="top:129.5pt;left:557.9pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Period</span></b></p>
<p style="top:124.8pt;left:608.3pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Outcome Measures</span></b></p>
<p style="top:124.8pt;left:707.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Main Results</span></b></p>
<p style="top:124.8pt;left:785.1pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">AE</span></b></p>
<p style="top:163.0pt;left:49.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9</span></p>
<p style="top:153.6pt;left:72.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Meng</span></p>
<p style="top:163.0pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2012)</span></p>
<p style="top:172.4pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:163.0pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:158.2pt;left:158.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">312</span></p>
<p style="top:167.8pt;left:147.4pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(156/156)</span></p>
<p style="top:158.2pt;left:209.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28.5</span></p>
<p style="top:167.7pt;left:204.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(18,48)</span></p>
<p style="top:163.0pt;left:284.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:153.5pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:163.0pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:172.4pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:148.8pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:158.2pt;left:429.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(A)</span></p>
<p style="top:167.7pt;left:434.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">+Control</span></p>
<p style="top:177.2pt;left:429.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">intervention</span></p>
<p style="top:158.2pt;left:498.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:167.7pt;left:489.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine(B)</span></p>
<p style="top:163.0pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 mo</span></p>
<p style="top:153.5pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:163.0pt;left:612.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Pregnancy rate</span></p>
<p style="top:172.4pt;left:611.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Recurrence rate</span></p>
<p style="top:149.1pt;left:710.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:158.5pt;left:701.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) 11.54%(TG) vs</span></p>
<p style="top:168.0pt;left:718.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">0%(CG)</span></p>
<p style="top:177.5pt;left:710.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:163.0pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:205.9pt;left:47.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10</span></p>
<p style="top:196.5pt;left:74.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Guo</span></p>
<p style="top:206.0pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2013)</span></p>
<p style="top:215.4pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:205.9pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:201.2pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">94</span></p>
<p style="top:210.7pt;left:150.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(48/46)</span></p>
<p style="top:191.7pt;left:193.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">TG: 32.0</span><i><span style="font-family:CMSY10,serif;font-size:8.3pt">&#xb1;</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9.6</span></p>
<p style="top:201.2pt;left:204.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(22,42)</span></p>
<p style="top:210.7pt;left:193.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CG: 31.0</span><i><span style="font-family:CMSY10,serif;font-size:8.3pt">&#xb1;</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7.8</span></p>
<p style="top:220.1pt;left:204.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(23,40)</span></p>
<p style="top:205.9pt;left:273.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Infertility</span></p>
<p style="top:191.7pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:201.2pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:210.7pt;left:350.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonograph,</span></p>
<p style="top:220.1pt;left:365.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CA125</span></p>
<p style="top:191.7pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:201.2pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:210.7pt;left:434.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">+Control</span></p>
<p style="top:220.1pt;left:429.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">intervention</span></p>
<p style="top:196.5pt;left:490.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Desogestrel</span></p>
<p style="top:205.9pt;left:489.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">and Ethinyl</span></p>
<p style="top:215.4pt;left:494.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Estradiol</span></p>
<p style="top:205.9pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:205.9pt;left:617.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Pregnancy rate</span></p>
<p style="top:206.2pt;left:714.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">b</span></sup></p>
<p style="top:205.9pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:243.9pt;left:47.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11</span></p>
<p style="top:234.4pt;left:75.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Liu</span></p>
<p style="top:243.9pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2017)</span></p>
<p style="top:253.3pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:243.9pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:239.1pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">72</span></p>
<p style="top:248.6pt;left:150.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(36/36)</span></p>
<p style="top:239.1pt;left:211.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:248.6pt;left:204.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(24,45)</span></p>
<p style="top:243.9pt;left:263.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea</span></p>
<p style="top:234.4pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:243.9pt;left:342.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gynecological exam,</span></p>
<p style="top:253.3pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography</span></p>
<p style="top:239.1pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:248.6pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:234.4pt;left:500.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sanjie</span></p>
<p style="top:243.9pt;left:493.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Zhentong</span></p>
<p style="top:253.3pt;left:496.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Capsule</span></p>
<p style="top:243.9pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:239.1pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:248.6pt;left:631.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) VAS</span></p>
<p style="top:239.1pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:248.6pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:243.9pt;left:782.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">none</span></p>
<p style="top:286.5pt;left:47.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12</span></p>
<p style="top:277.1pt;left:78.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Yi</span></p>
<p style="top:286.6pt;left:72.1pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(2018)</span></p>
<p style="top:296.0pt;left:75.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:286.5pt;left:111.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">RCT</span></p>
<p style="top:281.8pt;left:160.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">60</span></p>
<p style="top:291.3pt;left:150.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(30/30)</span></p>
<p style="top:267.6pt;left:210.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">TG:</span></p>
<p style="top:277.1pt;left:198.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">29.41</span><i><span style="font-family:CMSY10,serif;font-size:8.3pt">&#xb1;</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4.7</span></p>
<p style="top:286.5pt;left:208.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(n.r.)</span></p>
<p style="top:296.0pt;left:209.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">CG:</span></p>
<p style="top:305.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">30.0</span><i><span style="font-family:CMSY10,serif;font-size:8.3pt">&#xb1;</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4.1(n.r.)</span></p>
<p style="top:281.8pt;left:263.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dysmenorrhea,</span></p>
<p style="top:291.3pt;left:267.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dyspareunia</span></p>
<p style="top:272.3pt;left:360.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Symptom,</span></p>
<p style="top:281.8pt;left:348.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ultrasonography,</span></p>
<p style="top:291.3pt;left:349.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">antiendometrial</span></p>
<p style="top:300.7pt;left:348.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">antibody, CA125</span></p>
<p style="top:272.3pt;left:439.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal</span></p>
<p style="top:281.8pt;left:435.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">medicine</span></p>
<p style="top:291.3pt;left:434.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">+Control</span></p>
<p style="top:300.7pt;left:429.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">intervention</span></p>
<p style="top:286.5pt;left:491.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Gestrinone</span></p>
<p style="top:286.5pt;left:561.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 mo</span></p>
<p style="top:281.8pt;left:631.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) TER</span></p>
<p style="top:291.3pt;left:631.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) VAS</span></p>
<p style="top:281.8pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:291.3pt;left:710.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2) Positive</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span></sup></p>
<p style="top:286.5pt;left:785.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:318.9pt;left:57.3pt;line-height:6.0pt"><span style="font-family:URWPalladioL,serif;font-size:6.0pt">a</span><i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> &lt; 0.05;</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> b</span><i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> &lt; 0.01;</span><span style="font-family:URWPalladioL,serif;font-size:6.0pt"> c</span><i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> p</span></i><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> &lt; 0.001. TG: treatment group; CG: control group; SD: standard deviation; min: minimum; max: maximum; AE: Adverse event; n.r.: not reported; TER: total effectiveness rate; mo: month;</span></p>
<p style="top:329.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">VAS: visual analog scale; RCT: randomized controlled trial; NSD: no signi&#xfb01;cant difference; CA125: cancer antigen 125. Positive means that there was an improvement in the outcome. A lower VAS, recurrence</span></p>
<p style="top:339.1pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">rate, dysmenorrhea score, pelvic mass score, and CA124 meant an improvement with the status of endometriosis, and a higher TER indicated a better condition.</span></p>
<p style="top:367.8pt;left:166.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 4.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Dosing regimens of herbal medicines containing toxic animal-based medicinal materials in the included clinical studies.</span></p>
<p style="top:393.4pt;left:49.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study ID</span></b></p>
<p style="top:388.6pt;left:113.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:398.1pt;left:115.7pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:393.4pt;left:185.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal Medicine</span></b></p>
<p style="top:393.4pt;left:361.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Component</span></b></p>
<p style="top:388.6pt;left:514.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxic Animal-Based</span></b></p>
<p style="top:398.1pt;left:514.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medicinal Materials</span></b></p>
<p style="top:393.4pt;left:627.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosage, Frequency</span></b></p>
<p style="top:393.4pt;left:731.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosing Period</span></b></p>
<p style="top:431.3pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">1</span></p>
<p style="top:421.8pt;left:120.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Wu</span></p>
<p style="top:431.3pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(1993)</span></p>
<p style="top:440.7pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:431.3pt;left:211.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:412.4pt;left:299.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sparganii Rhizoma 9 g, Curcumae Rhizoma 8 g,</span></p>
<p style="top:421.8pt;left:285.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Liquidambaris Fructus 9 g, Hirudo 9 g, Paeoniae Radix</span></p>
<p style="top:431.3pt;left:292.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rubra 9 g, Manitis Squama 12 g, Eupolyphaga 12 g,</span></p>
<p style="top:440.7pt;left:283.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Moutan Radicis Cortex 12 g, Salviae Miltiorrhizae Radix</span></p>
<p style="top:450.2pt;left:298.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 g, Cyperi Rhizoma 12 g, Prunellae Spica 12 g</span></p>
<p style="top:431.3pt;left:512.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Eupolyphaga, Hirudo</span></p>
<p style="top:431.3pt;left:655.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:421.8pt;left:737.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medication</span></p>
<p style="top:431.3pt;left:721.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">discontinued during</span></p>
<p style="top:440.7pt;left:734.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation</span></p>
<p style="top:473.9pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2</span></p>
<p style="top:464.5pt;left:114.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Zhang</span></p>
<p style="top:473.9pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2007)</span></p>
<p style="top:483.4pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:473.9pt;left:211.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:464.5pt;left:286.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Salviae Miltiorrhizae Radix, Persicae Semen, Corydalis</span></p>
<p style="top:473.9pt;left:291.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Tuber, Curcumae Rhizoma, Hirudo, Linderae Radix,</span></p>
<p style="top:483.4pt;left:313.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Olibanum, Myrrha, Cinnamomi Cortex</span></p>
<p style="top:473.9pt;left:537.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo</span></p>
<p style="top:473.9pt;left:623.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, bid</span></p>
<p style="top:473.9pt;left:752.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:779.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 of 21</span></p>
<p style="top:94.5pt;left:393.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 4.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:120.0pt;left:49.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study ID</span></b></p>
<p style="top:115.3pt;left:113.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:124.8pt;left:115.7pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:120.0pt;left:185.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal Medicine</span></b></p>
<p style="top:120.0pt;left:361.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Component</span></b></p>
<p style="top:115.3pt;left:514.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxic Animal-Based</span></b></p>
<p style="top:124.8pt;left:514.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medicinal Materials</span></b></p>
<p style="top:120.0pt;left:627.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosage, Frequency</span></b></p>
<p style="top:120.0pt;left:731.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosing Period</span></b></p>
<p style="top:157.9pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3</span></p>
<p style="top:148.5pt;left:121.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Xu</span></p>
<p style="top:157.9pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2007)</span></p>
<p style="top:167.4pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:153.2pt;left:175.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Leech Tongluo Capsule</span></p>
<p style="top:162.7pt;left:169.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Shuizhi tongluo jiaonang)</span></p>
<p style="top:139.1pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Hirudo 0.5 g, Manitis Squama 0.5 g, Astragali Radix 0.5 g,</span></p>
<p style="top:148.5pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Draconis Sanguis 0.5 g, Codonopsis Pilosulae Radix 0.5 g,</span></p>
<p style="top:157.9pt;left:293.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sparganii Rhizoma 0.5 g, Curcumae Rhizoma 0.5 g,</span></p>
<p style="top:167.4pt;left:287.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Scolopendra 0.5 g, Cnidii Rhizoma 0.5 g, Glycyrrhizae</span></p>
<p style="top:176.9pt;left:342.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Radix et Rhizoma 0.5 g</span></p>
<p style="top:157.9pt;left:513.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo, Scolopendra</span></p>
<p style="top:153.2pt;left:629.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Six granules/time,</span></p>
<p style="top:162.7pt;left:656.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">tid</span></p>
<p style="top:157.9pt;left:734.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From MCD 5</span></p>
<p style="top:214.8pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4</span></p>
<p style="top:205.3pt;left:114.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Zhang</span></p>
<p style="top:214.8pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2007)</span></p>
<p style="top:224.3pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:205.3pt;left:176.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Quyu Jiedu Xiaozheng</span></p>
<p style="top:214.8pt;left:199.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Decoction</span></p>
<p style="top:224.3pt;left:165.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Quyu Jiedu Xiaozheng tang)</span></p>
<p style="top:191.2pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Sargentodoxa cuneata 15&#x2013;30 g, Hedyotidis Herba 15&#x2013;30 g,</span></p>
<p style="top:200.6pt;left:284.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Astragali Radix 30 g, Coicis Semen 30 g, Scapharcae seu</span></p>
<p style="top:210.1pt;left:285.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Tegillarcae Concha 15 g, Litchi Semen 15 g, Cremastrae</span></p>
<p style="top:219.5pt;left:286.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Tuber 9&#x2013;12 g, Draconis Sanguis 6&#x2013;9 g, Olibanum 6&#x2013;9 g,</span></p>
<p style="top:229.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Myrrha 6&#x2013;9 g, Eupolyphaga 6 g, Scolopendra 1&#x2013;2 pieces,</span></p>
<p style="top:238.5pt;left:282.6pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Agastachis Herba 9 g, Glycyrrhizae Radix et Rhizoma 6 g</span></p>
<p style="top:214.8pt;left:503.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Eupolyphaga, Scolopendra</span></p>
<p style="top:214.8pt;left:623.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, n.r.</span></p>
<p style="top:214.8pt;left:752.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:290.6pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5</span></p>
<p style="top:281.1pt;left:117.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Feng</span></p>
<p style="top:290.6pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2014)</span></p>
<p style="top:300.1pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:290.6pt;left:181.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Xiaoyi Zhuyun tang</span></p>
<p style="top:252.7pt;left:288.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Angelicae Gigantis Radix 12 g, Paeoniae Radix Rubra</span></p>
<p style="top:262.2pt;left:288.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 g, Paeoniae Radix Alba 12 g, Cyperi Rhizoma 12 g,</span></p>
<p style="top:271.7pt;left:289.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Morindae Radix 12 g, Patriniae Radix 12 g, Sparganii</span></p>
<p style="top:281.1pt;left:284.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rhizoma 20 g, Curcumae Rhizoma 20 g, Astragali Radix</span></p>
<p style="top:290.6pt;left:298.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">20 g, Galli Gigeriae Endothelium Corneum 20 g,</span></p>
<p style="top:300.1pt;left:285.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Gleditsiae Spina 20 g, Lycopi Herba 20 g, Dipsaci Radix</span></p>
<p style="top:309.5pt;left:286.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">20 g, Drynariae Rhizoma 20 g, Eucommiae Cortex 20 g,</span></p>
<p style="top:319.0pt;left:283.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Coicis Semen 20 g, Bupleuri Radix 9 g, Hirudo 6 g, Cervi</span></p>
<p style="top:328.4pt;left:363.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cornu 10 g</span></p>
<p style="top:290.6pt;left:537.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo</span></p>
<p style="top:290.6pt;left:623.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, bid</span></p>
<p style="top:285.9pt;left:719.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From MCD 6 to MCD</span></p>
<p style="top:295.3pt;left:736.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 (10 days)</span></p>
<p style="top:357.1pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6</span></p>
<p style="top:347.1pt;left:118.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Han</span></p>
<p style="top:356.5pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2009)</span></p>
<p style="top:366.0pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:342.7pt;left:183.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">A</span></p>
<p style="top:342.7pt;left:241.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:342.7pt;left:359.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo 4&#x2013;5 g</span></p>
<p style="top:342.7pt;left:537.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo</span></p>
<p style="top:356.6pt;left:648.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r., bid</span></p>
<p style="top:347.9pt;left:720.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From 3&#x2013;4 days before</span></p>
<p style="top:357.3pt;left:715.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation to the end</span></p>
<p style="top:366.8pt;left:729.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">of menstruation</span></p>
<p style="top:361.6pt;left:184.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">B</span></p>
<p style="top:361.6pt;left:241.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:352.2pt;left:285.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Salviae Miltiorrhizae Radix 10&#x2013;15 g, Angelicae Gigantis</span></p>
<p style="top:361.7pt;left:283.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Radix 8&#x2013;10 g, Salvia chinensis Benth 8&#x2013;10 g, Myrrha 10 g,</span></p>
<p style="top:371.1pt;left:308.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sparganii Rhizoma 8 g, Leonuri Herba 8 g</span></p>
<p style="top:409.0pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7</span></p>
<p style="top:399.6pt;left:114.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Zhang</span></p>
<p style="top:409.0pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2009)</span></p>
<p style="top:418.5pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:399.6pt;left:176.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Quyu Jiedu Xiaozheng</span></p>
<p style="top:409.0pt;left:199.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Decoction</span></p>
<p style="top:418.5pt;left:165.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Quyu Jiedu Xiaozheng tang)</span></p>
<p style="top:385.4pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Sargentodoxa cuneata 30 g, Hedyotidis Herba 30 g, Coicis</span></p>
<p style="top:394.8pt;left:296.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Semen 30 g, Astragali Radix 30 g, Scapharcae seu</span></p>
<p style="top:404.3pt;left:285.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Tegillarcae Concha 15 g, Litchi Semen 15 g, Cremastrae</span></p>
<p style="top:413.8pt;left:282.7pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Tuber 10 g, Agastachis Herba 9 g, Scolopendra two pieces,</span></p>
<p style="top:423.2pt;left:287.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Draconis Sanguis 6 g, Eupolyphaga 6 g, Olibanum 6 g,</span></p>
<p style="top:432.7pt;left:299.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Myrrha 6 g, Glycyrrhizae Radix et Rhizoma 6 g</span></p>
<p style="top:409.0pt;left:503.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Eupolyphaga, Scolopendra</span></p>
<p style="top:409.0pt;left:623.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, bid</span></p>
<p style="top:409.0pt;left:752.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:456.4pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8</span></p>
<p style="top:447.0pt;left:120.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Lin</span></p>
<p style="top:456.4pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2011)</span></p>
<p style="top:465.9pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:447.0pt;left:171.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Whole scorpion bergamot</span></p>
<p style="top:456.4pt;left:202.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">powder</span></p>
<p style="top:465.9pt;left:178.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Quanxie Foshou san)</span></p>
<p style="top:451.7pt;left:295.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Scorpio 6 g, Angelicae Gigantis Radix 15 g, Cnidii</span></p>
<p style="top:461.2pt;left:283.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rhizoma 10 g, Leonuri Herba 15 g, Cyperi Rhizoma 15 g</span></p>
<p style="top:456.4pt;left:537.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Scorpio</span></p>
<p style="top:456.4pt;left:623.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, n.r.</span></p>
<p style="top:451.7pt;left:720.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From 3&#x2013;4 days before</span></p>
<p style="top:461.2pt;left:734.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation</span></p>


<p style="top:50.4pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:50.4pt;left:779.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11 of 21</span></p>
<p style="top:94.5pt;left:393.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 4.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:120.0pt;left:49.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Study ID</span></b></p>
<p style="top:115.3pt;left:113.4pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Author</span></b></p>
<p style="top:124.8pt;left:115.7pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Year)</span></b></p>
<p style="top:120.0pt;left:185.8pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Herbal Medicine</span></b></p>
<p style="top:120.0pt;left:361.2pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Component</span></b></p>
<p style="top:115.3pt;left:514.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxic Animal-Based</span></b></p>
<p style="top:124.8pt;left:514.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Medicinal Materials</span></b></p>
<p style="top:120.0pt;left:627.0pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosage, Frequency</span></b></p>
<p style="top:120.0pt;left:731.5pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Dosing Period</span></b></p>
<p style="top:162.4pt;left:64.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9</span></p>
<p style="top:152.4pt;left:116.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Meng</span></p>
<p style="top:161.8pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2012)</span></p>
<p style="top:171.3pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:139.0pt;left:183.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">A</span></p>
<p style="top:139.0pt;left:241.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:139.0pt;left:359.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo 1&#x2013;2 g</span></p>
<p style="top:139.0pt;left:537.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo</span></p>
<p style="top:161.4pt;left:649.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r., tid</span></p>
<p style="top:152.6pt;left:720.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From 3&#x2013;4 days before</span></p>
<p style="top:162.1pt;left:715.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation to the end</span></p>
<p style="top:171.6pt;left:729.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">of menstruation</span></p>
<p style="top:167.4pt;left:184.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">B</span></p>
<p style="top:167.4pt;left:241.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r.</span></p>
<p style="top:148.5pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Angelicae Gigantis Radix 10&#x2013;15 g, Cnidii Rhizoma 6&#x2013;10 g,</span></p>
<p style="top:158.0pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Leonuri Herba 15 g, Paeoniae Radix Rubra 10 g, Paeoniae</span></p>
<p style="top:167.4pt;left:294.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Radix Alba 10 g, Curcumae Longae Rhizoma 10 g,</span></p>
<p style="top:176.9pt;left:295.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sparganii Rhizoma 10 g, Curcumae Rhizoma 10 g,</span></p>
<p style="top:186.3pt;left:291.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Sargentodoxa cuneata 30 g, Sepiae Endoconcha 12 g</span></p>
<p style="top:224.3pt;left:62.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10</span></p>
<p style="top:214.8pt;left:118.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Guo</span></p>
<p style="top:224.3pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2013)</span></p>
<p style="top:233.7pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:219.5pt;left:173.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bushen Quyu Decoction</span></p>
<p style="top:229.0pt;left:180.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Bushen Quyu tang)</span></p>
<p style="top:200.6pt;left:289.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Lycii Fructus 15 g, Rehmanniae Radix Preparata 15 g,</span></p>
<p style="top:210.1pt;left:294.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Ligustri Lucidi Fructus 15 g, Cuscutae Semen 15 g,</span></p>
<p style="top:219.5pt;left:288.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Angelicae Gigantis Radix 10 g, Paeoniae Radix Rubra</span></p>
<p style="top:229.0pt;left:284.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 g, Paeoniae Radix Alba 15 g, Achyranthis Radix 12 g,</span></p>
<p style="top:238.5pt;left:290.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Bupleuri Radix 10 g, Sappan Lignum 10 g, Sparganii</span></p>
<p style="top:247.9pt;left:290.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rhizoma 10 g, Curcumae Rhizoma 10 g, Hirudo 10 g</span></p>
<p style="top:224.3pt;left:537.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Hirudo</span></p>
<p style="top:224.3pt;left:623.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, bid</span></p>
<p style="top:224.3pt;left:734.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From MCD 1</span></p>
<p style="top:276.4pt;left:62.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11</span></p>
<p style="top:266.9pt;left:120.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Liu</span></p>
<p style="top:276.4pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2017)</span></p>
<p style="top:285.9pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:271.7pt;left:176.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Tongjingxiao Granules</span></p>
<p style="top:281.1pt;left:183.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Tongjingxiao keli)</span></p>
<p style="top:262.2pt;left:285.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Salviae Miltiorrhizae Radix 20 g, Paeoniae Radix Rubra</span></p>
<p style="top:271.7pt;left:289.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">20 g, Angelicae Gigantis Radix 10 g, Scolopendra 6 g,</span></p>
<p style="top:281.1pt;left:284.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Corydalis Tuber 20 g, Meliae Fructus 10 g, Glycyrrhizae</span></p>
<p style="top:290.6pt;left:345.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Radix et Rhizoma 6 g</span></p>
<p style="top:276.4pt;left:528.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Scolopendra</span></p>
<p style="top:276.4pt;left:623.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">One dose per day, bid</span></p>
<p style="top:266.9pt;left:724.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From 7 days before</span></p>
<p style="top:276.4pt;left:715.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation to the end</span></p>
<p style="top:285.9pt;left:729.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">of menstruation</span></p>
<p style="top:319.1pt;left:62.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12</span></p>
<p style="top:309.6pt;left:122.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Yi</span></p>
<p style="top:319.1pt;left:116.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(2018)</span></p>
<p style="top:328.5pt;left:119.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">]</span></p>
<p style="top:314.3pt;left:177.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Xiaoyi Analgesic Soup</span></p>
<p style="top:323.8pt;left:178.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Xiaoyi Zhitong tang)</span></p>
<p style="top:304.9pt;left:282.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cinnamomi Ramulus 20 g, Poria Sclerotium 30 g, Salviae</span></p>
<p style="top:314.3pt;left:282.9pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Miltiorrhizae Radix 20 g, Persicae Semen 20 g, Curcumae</span></p>
<p style="top:323.8pt;left:289.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Rhizoma 10 g, Scolopendra two pieces, Eupolyphaga</span></p>
<p style="top:333.2pt;left:308.5pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 g, Hirudo 10 g, Pelodiscis Carapax 20 g</span></p>
<p style="top:314.3pt;left:511.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Eupolyphaga, Hirudo,</span></p>
<p style="top:323.8pt;left:528.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Scolopendra</span></p>
<p style="top:319.1pt;left:648.2pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r., bid</span></p>
<p style="top:314.3pt;left:729.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">From the end of</span></p>
<p style="top:323.8pt;left:734.1pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">menstruation</span></p>
<p style="top:348.0pt;left:271.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">n.r., not reported; bid, twice a day; tid, three times a day; MCD, menstrual cycle day.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 of 21</span></p>
<p style="top:87.7pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4. Discussion</span></b></p>
<p style="top:103.2pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In this scoping review, we outlined preclinical and clinical studies of toxic animal-</span></p>
<p style="top:115.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">based medicinal materials for the treatment of endometriosis. By reviewing the exper-</span></p>
<p style="top:128.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">imental and clinical studies included in this study, we identi&#xfb01;ed the potential of toxic</span></p>
<p style="top:140.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">animal-based medicinal materials as a treatment of endometriosis. However, the current</span></p>
<p style="top:153.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">evidence is insuf&#xfb01;cient for establishing a standard for endometriosis treatment with toxic</span></p>
<p style="top:166.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">animal-based medicinal materials. High-quality studies are needed to investigate the</span></p>
<p style="top:178.6pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">various action mechanisms of toxic animal-based medical materials against endometriosis.</span></p>
<p style="top:191.2pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Even though we did not impose any restrictions in the literature search, we found more</span></p>
<p style="top:203.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">studies published in China than in any other country. Traditional Korean medicine and</span></p>
<p style="top:216.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">traditional Chinese medicine were alike as both are recognized by the healthcare systems</span></p>
<p style="top:228.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of those counties. However, in the healthcare systems of the two countries, traditional</span></p>
<p style="top:241.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Chinese medicine has a bigger share than that of traditional Korean medicine. Furthermore,</span></p>
<p style="top:253.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">traditional Chinese medicine spans a broader range, as it includes not only traditional</span></p>
<p style="top:266.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Chinese medicine but also the integration of Chinese and Western medicine [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Therefore,</span></p>
<p style="top:279.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">it is believed that there would be more cases of using toxic animal-based medicinal materials</span></p>
<p style="top:291.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in clinical contexts in China, with more reports for that matter.</span></p>
<p style="top:304.1pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The toxic animal-based medical materials investigated in the preclinical and clinical</span></p>
<p style="top:316.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies included in this analysis were somewhat different. Hirudo and Scolopendra were</span></p>
<p style="top:329.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">used in both preclinical and clinical studies. In contrast, Eupolyphaga and Scorpio were</span></p>
<p style="top:341.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">used only in clinical studies, and bufalin, bee venom, and snake venom were used only in</span></p>
<p style="top:354.3pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">preclinical studies. This is because Bufonis Venenum, bee venom, and snake venom are</span></p>
<p style="top:366.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">animal-derived toxins that can cause serious side effects, including death [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">48</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">51</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], and</span></p>
<p style="top:379.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">thus have not been traditionally used to treat endometriosis and benign disease. Although</span></p>
<p style="top:391.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">these three animal venoms have recently been reported to exert proapoptotic</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">52</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">54</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span></p>
<p style="top:404.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and anti-in&#xfb02;ammatory effects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">56</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], there has been no clinical evidence of their bene&#xfb01;t</span></p>
<p style="top:417.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in endometriosis treatment. These three venoms are thought to be effective against en-</span></p>
<p style="top:429.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dometriosis because they have been reported to induce apoptosis, inhibit angiogenesis,</span></p>
<p style="top:442.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reduce estrogen levels, suppress MMP-9 expression, and exert anti-in&#xfb02;ammatory effects</span></p>
<p style="top:454.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in preclinical studies. However, considering the serious side effects that may occur, the</span></p>
<p style="top:467.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> toxicity and action mechanisms of bufo venom, bee venom, and snake</span></p>
<p style="top:479.9pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">venom must be elucidated before their ef&#xfb01;cacy against endometriosis can be investigated</span></p>
<p style="top:492.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in clinical trials.</span></p>
<p style="top:504.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The 12 clinical studies included in this study reported improvement of various en-</span></p>
<p style="top:517.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">dometriosis symptoms, such as dysmenorrhea, pelvic pain, dyspareunia, mittelschmerz,</span></p>
<p style="top:530.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">anal pain, as well as increased pregnancy rate after administration of a decoction containing</span></p>
<p style="top:542.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Hirudo, Eupolyphaga, Scolopendra, and Scorpio. However, as there were differences in the</span></p>
<p style="top:555.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">symptoms, dosage, and dosing period of the toxic animal-based medicinal materials used,</span></p>
<p style="top:567.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the evidence was considered insuf&#xfb01;cient for establishing a standard for the application</span></p>
<p style="top:580.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of toxic animal-based medicinal materials in the treatment of endometriosis. In future</span></p>
<p style="top:592.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">studies, the optimal dosage of the medicines should be established with consideration for</span></p>
<p style="top:605.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">both ef&#xfb01;cacy and toxicity, and clinical studies must be conducted to standardize the dosing</span></p>
<p style="top:617.9pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">period and dosage.</span></p>
<p style="top:630.4pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The most widely used toxic animal-based medicinal material among the included</span></p>
<p style="top:643.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">clinical studies was Hirudo Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. Hirudo is the dried entire body of</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Whitmania pigra</span></i></p>
<p style="top:655.5pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Whitman,</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Hirudo nipponica</span></i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Whitman, or</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> W. acranulata</span></i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Whitman, and is a representative</span></p>
<p style="top:668.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">toxic animal-based medicinal material that has been used since the beginning of civilization.</span></p>
<p style="top:680.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">It has the ef&#xfb01;cacy of &#x201c;breaking blood and expelling stasis&#x201d;, and there is historical evidence</span></p>
<p style="top:693.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of its use in the treatment of endometriosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">58</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. However, it is dif&#xfb01;cult to con&#xfb01;rm</span></p>
<p style="top:705.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the effectiveness of Hirudo against endometriosis, as there were no studies examining</span></p>
<p style="top:718.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">only Hirudo. Nevertheless, a medicinal decoction containing Hirudo was shown to exert</span></p>
<p style="top:730.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">therapeutic effect against endometriosis in both preclinical and clinical studies.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">13 of 21</span></p>
<p style="top:60.6pt;left:41.6pt;line-height:8.0pt"><i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">Toxins </span></i><b><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">2021</span></b><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, </span><i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">13</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, x FOR PEER REVIEW </span></p>
<p style="top:60.6pt;left:542.0pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">2 of 24 </span></p>
<p style="top:67.2pt;left:41.6pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt"> </span></p>
<p style="top:821.9pt;left:41.6pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:206.1pt;left:328.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:206.1pt;left:489.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:222.1pt;left:223.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">(A) Hirudo                       (B) Scorpio. </span></p>
<p style="top:351.0pt;left:328.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:351.0pt;left:489.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:366.9pt;left:220.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">(C) Scolopendra                  (D) Eupolyphaga </span></p>
<p style="top:385.6pt;left:172.1pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Figure 2. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Toxic animal-based medicinal material in the includes clinical studies. (</span><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">A</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">) Hirudo : The </span></p>
<p style="top:397.1pt;left:172.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">dried entire body of </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Whitmania pigra</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> Whitman, </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Hirudo nipponica</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> Whitman, or </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">W. acranulata</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span></p>
<p style="top:408.6pt;left:172.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Whitman. (</span><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">B</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">) Scorpio : The dried body of </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Buthus martensii</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> Karsch scorpion. (</span><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">C</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">) Scolopendra : The </span></p>
<p style="top:420.1pt;left:172.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">dried body of </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Scolopendra</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">subspinipes mutilans</span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> L. Koch. (</span><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">D</span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">) Eupolyphaga : The dried body of </span></p>
<p style="top:431.7pt;left:172.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">female </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Eupolyphaga sinensis </span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Walker or </span><i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Steleophaga plancyi </span></i><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">(Boleny). </span></p>
<p style="top:455.4pt;left:193.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">The most widely used toxic animal-based medicinal material among the included </span></p>
<p style="top:468.2pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">clinical studies was Hirudo. Hirudo is the dried entire body of </span><i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Whitmania pigra</span></i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> Whitman, </span></p>
<p style="top:481.1pt;left:172.1pt;line-height:10.0pt"><i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Hirudo nipponica</span></i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> Whitman, or </span><i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">W. acranulata</span></i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> Whitman, and is a representative toxic animal-</span></p>
<p style="top:493.9pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">based medicinal material that has been used since the beginning of civilization. It has the </span></p>
<p style="top:506.8pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">efficacy of &#x201c;break</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">ing blood and expelling </span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">stasis&#x201d;</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">, and there is historical evidence of its use </span></p>
<p style="top:519.5pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">in the treatment of endometriosis [22,57,58]. However, it is difficult to confirm the </span></p>
<p style="top:532.3pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">effectiveness of Hirudo against endometriosis, as there were no studies examining only </span></p>
<p style="top:545.2pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Hirudo. Nevertheless, a medicinal decoction containing Hirudo was shown to exert </span></p>
<p style="top:558.0pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">therapeutic effect against endometriosis in both preclinical and clinical studies.  </span></p>
<p style="top:570.8pt;left:193.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">In the studies included in this scoping review, medicinal decoctions containing </span></p>
<p style="top:583.6pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Hirudo was shown to downregulate the expression of hypoxia-inducible factor 1-alpha </span></p>
<p style="top:596.4pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">(HIF-</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">1&#x3b1;)</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> and reduce the level of vascular endothelial growth factor (VEGF), thereby </span></p>
<p style="top:609.2pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">suppressing the progression of endometriosis [32]. They also reduced the levels of basic </span></p>
<p style="top:622.1pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">fibroblast growth factor, platelet-derived growth factor, and VEGF, and were involved in </span></p>
<p style="top:635.0pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">the angiogenesis pathway by downregulating TLR4 and NF-</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">&#x3ba;B</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">, which participate in the </span></p>
<p style="top:647.7pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">signaling process of angiogenesis, thus improving endometriosis [31]. It was also </span></p>
<p style="top:660.5pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">suggested that a medical decoction containing Hirudo exerted anti-inflammatory effect </span></p>
<p style="top:673.4pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">[33]. These findings are supported by other experimental studies. Hirudo has been </span></p>
<p style="top:686.2pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">revealed to</span><i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></i><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">have anticoagulant, anti-inflammatory, bacteriostatic, and analgesic effects </span></p>
<p style="top:699.0pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">[22,59]. Hirudo is also known to inhibit tumor angiogenesis by improving the tumor </span></p>
<p style="top:711.8pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">hypoxia microenvironment, reducing the mRNA and protein expression of HIF-</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">1&#x3b1;</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">, and </span></p>
<p style="top:724.6pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">contributing to the downregulation of VEGF mRNA expression [60]. In addition, Hirudo </span></p>
<p style="top:737.4pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">induces apoptosis and inhibits cell proliferation in Hep G2 human liver cancer cells and </span></p>
<p style="top:750.3pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">HL-60 leukemic cells, resulting in an antitumor effect [61,62]. Although the use of Hirudo </span></p>
<p style="top:763.1pt;left:172.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">is controversial, Hirudo exerts anti-inflammatory effect by inhibiting carboxypeptidases </span></p>
<img style="position:absolute;transform:matrix(.43750177,0,-0,.43554277,96.22934,35.993318)" src="data:image/jpeg;base64,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">
<img style="position:absolute;transform:matrix(.43566738,0,-0,.43806765,309.896,36.993318)" src="data:image/jpeg;base64,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==">
<img style="position:absolute;transform:matrix(.43750177,0,-0,.4445098,96.22934,232.08667)" src="data:image/jpeg;base64,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">
<img style="position:absolute;transform:matrix(.43384833,0,-0,.43806765,308.896,230.08667)" src="data:image/jpeg;base64,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">
<p style="top:389.3pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Toxic animal-based medicinal material in the includes clinical studies. (</span><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">) Hirudo: The</span></p>
<p style="top:402.2pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">dried entire body of</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Whitmania pigra</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Whitman,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Hirudo nipponica</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Whitman, or</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> W. acranulata</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Whitman.</span></p>
<p style="top:415.0pt;left:167.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">(</span><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">) Scorpio: The dried body of</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Buthus martensii</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Karsch scorpion. (</span><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">C</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">) Scolopendra: The dried body of</span></p>
<p style="top:427.7pt;left:167.0pt;line-height:9.1pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Scolopendra subspinipes mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> L. Koch. (</span><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">D</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">) Eupolyphaga: The dried body of female</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Eupolyphaga</span></i></p>
<p style="top:440.6pt;left:167.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">sinensis</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Walker or</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Steleophaga plancyi</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (Boleny).</span></p>
<p style="top:462.3pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In the studies included in this scoping review, medicinal decoctions containing Hirudo</span></p>
<p style="top:474.7pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was shown to downregulate the expression of hypoxia-inducible factor 1-alpha (HIF-1</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">)</span></p>
<p style="top:487.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and reduce the level of vascular endothelial growth factor (VEGF), thereby suppressing the</span></p>
<p style="top:499.8pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">progression of endometriosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. They also reduced the levels of basic &#xfb01;broblast growth</span></p>
<p style="top:512.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">factor, platelet-derived growth factor, and VEGF, and were involved in the angiogenesis</span></p>
<p style="top:524.9pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pathway by downregulating TLR4 and NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">B, which participate in the signaling process</span></p>
<p style="top:537.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of angiogenesis, thus improving endometriosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. It was also suggested that a medical</span></p>
<p style="top:550.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">decoction containing Hirudo exerted anti-in&#xfb02;ammatory effect [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. These &#xfb01;ndings are</span></p>
<p style="top:562.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">supported by other experimental studies. Hirudo has been revealed to have anticoagulant,</span></p>
<p style="top:575.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">anti-in&#xfb02;ammatory, bacteriostatic, and analgesic effects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Hirudo is also known to</span></p>
<p style="top:587.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibit tumor angiogenesis by improving the tumor hypoxia microenvironment, reducing</span></p>
<p style="top:600.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the mRNA and protein expression of HIF-1</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">, and contributing to the downregulation</span></p>
<p style="top:612.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of VEGF mRNA expression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">60</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In addition, Hirudo induces apoptosis and inhibits cell</span></p>
<p style="top:625.3pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">proliferation in Hep G2 human liver cancer cells and HL-60 leukemic cells, resulting in</span></p>
<p style="top:637.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">an antitumor effect [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">62</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Although the use of Hirudo is controversial, Hirudo exerts</span></p>
<p style="top:650.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">anti-in&#xfb02;ammatory effect by inhibiting carboxypeptidases (kininase 1), inhibits platelet</span></p>
<p style="top:663.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">function, exerts anticoagulant activity, and increases blood &#xfb02;ow [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">63</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:675.6pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Scolopendra was the second-most widely used toxic animal-based medicinal material</span></p>
<p style="top:688.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in the included clinical studies. Scolopendra is the dried body of</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Scolopendra subspinipes</span></i></p>
<p style="top:700.6pt;left:167.3pt;line-height:10.1pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> L. Koch, which is poisonous. It has the ef&#xfb01;cacy of &#x201c;extinguishing wind and</span></p>
<p style="top:713.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">suppressing convulsion, unblocking collaterals and relieving pain, counteracting toxins,</span></p>
<p style="top:725.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and dissipating masses&#x201d; and is used for &#x201c;spasm and convulsion due to internal stirring</span></p>
<p style="top:738.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of liver wind, etc.&#x201d; [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Medicinal decoctions containing Scolopendra were shown to be</span></p>
<p style="top:750.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">effective in treating endometriosis in both clinical and preclinical studies included in the</span></p>
<p style="top:763.4pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">present review.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">14 of 21</span></p>
<p style="top:97.4pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Experimental studies included in this study suggested that medical decoctions con-</span></p>
<p style="top:110.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">taining Scolopendra may exert therapeutic effect against endometriosis, which is a chronic</span></p>
<p style="top:122.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in&#xfb02;ammatory condition, through anti-in&#xfb02;ammatory action [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. This is supported by other</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies, in which Scolopendra was reported to have anticoagulation, antiseptic, and anti-</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in&#xfb02;ammatory effects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">64</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">66</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Scolopendra is also known to induce the downregulation</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of matrix metallopeptidase-2 (MMP-2) and -9 in tumor cells, suppress the migration and</span></p>
<p style="top:172.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">invasion of tumor cells, and inhibit cell proliferation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">67</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In addition, Scolopendra inhibits</span></p>
<p style="top:185.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the proliferation of EGFR-overexpressing cells by inducing apoptosis and modulating the</span></p>
<p style="top:198.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">EGFR pathway [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">68</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">69</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It also exerts anti-in&#xfb02;ammatory activity partially through inhibition</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of the NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">B signaling pathway [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">70</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:222.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Eupolyphaga, the third-most commonly used toxic animal-based medicinal mate-</span></p>
<p style="top:235.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">rial in this review, is the dried body of female</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Eupolyphaga sinensis</span></i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Walker or</span><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Steleophaga</span></i></p>
<p style="top:248.0pt;left:167.3pt;line-height:10.1pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.1pt">plancyi</span></i><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> (Boleny), which is slightly poisonous. It has the ef&#xfb01;cacy of &#x201c;breaking blood and</span></p>
<p style="top:260.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">expelling stasis&#x201d; and has been used clinically for &#x201c;aggregation-accumulation due to static</span></p>
<p style="top:273.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">blood obstruction&#x201d; [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Clinical studies in this review revealed that medicinal decoctions</span></p>
<p style="top:285.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">containing Eupolyphaga were effective in alleviating endometriosis symptoms. However,</span></p>
<p style="top:298.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">there have been no experimental studies that elucidate the anti-endometriosis mechanism</span></p>
<p style="top:310.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of Eupolyphaga. Nevertheless, in other studies, Eupolyphaga was shown to inhibit cell</span></p>
<p style="top:323.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">adhesion to &#xfb01;bronectin and collagen IV as well as cell migration and invasion in A549</span></p>
<p style="top:335.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">human lung cancer cell [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">71</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. It also inhibits cell proliferation and reduces MMP-2 and -9</span></p>
<p style="top:348.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">expression in hepatocellular carcinoma [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">72</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], and reduces cell invasive ability by downregu-</span></p>
<p style="top:361.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">lating MMP-2 and -9 protein expression in breast cancer [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">73</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Furthermore, it induces the</span></p>
<p style="top:373.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">detachment and apoptosis of A549 human lung cancer cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">71</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], inhibits tumor cell growth</span></p>
<p style="top:386.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in hepatocarcinoma, promotes TNF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and IFN-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b3;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> expression, increases the Bax/Bcl-2 ratio,</span></p>
<p style="top:398.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and activates caspases-3 to induce apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">74</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Moreover, Eupolyphaga is known to</span></p>
<p style="top:411.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">activate the immune function by modulating oxidative systems, enhancing the phagocytic</span></p>
<p style="top:423.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">function of macrophages, and elevating serum IL-2 level [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">75</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:436.4pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Lastly, the dried body of</span><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Buthus martensii</span></i><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Karsch scorpion is known to be poisonous</span></p>
<p style="top:448.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and exert liver-pacifying and wind-extinguishing effects. Scorpio has pharmacological</span></p>
<p style="top:461.6pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">properties, such as pain-reducing, anti-in&#xfb02;ammatory, and anticoagulant properties [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">76</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">77</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">],</span></p>
<p style="top:474.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">but no experimental studies have determined the therapeutic mechanism of Scorpio against</span></p>
<p style="top:486.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">endometriosis. Scorpio exerts an antitumor effect by inhibiting cell proliferation, inducing</span></p>
<p style="top:499.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptosis, and decreasing migration and invasive functions in Hepa 1&#x2013;6 cells and HepG2</span></p>
<p style="top:511.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">78</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">79</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. They also inhibit MMP activity in breast and colorectal cancers, thereby</span></p>
<p style="top:524.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">reducing the motility and invasion of tumor cells, and induce apoptosis by decreasing the</span></p>
<p style="top:536.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">expression of antiapoptotic proteins and increasing that of proapoptotic proteins [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">80</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In</span></p>
<p style="top:549.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">addition, chlorotoxin derived from scorpion toxin inhibits the expression of ER</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> in breast</span></p>
<p style="top:561.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cancer cells by inhibiting the ER</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> signaling pathway through direct binding to ER</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, thus</span></p>
<p style="top:574.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">changing the protein secondary structure of its LBD domain [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">81</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:587.0pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">As outlined above, toxic animal-based medicinal materials are composed of several</span></p>
<p style="top:599.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">molecules that exhibit a wide range of pharmacological activities. Considering that en-</span></p>
<p style="top:612.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dometriosis has several possible mechanisms of pathogenesis, multi-target medicines</span></p>
<p style="top:624.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">have the potential to treat endometriosis through multiple pathways. Further research is</span></p>
<p style="top:637.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">needed to elucidate the speci&#xfb01;c therapeutic mechanisms of individual toxic animal-based</span></p>
<p style="top:649.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">medicinal materials against endometriosis. Although the mechanisms underlying the pro-</span></p>
<p style="top:662.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">gression of endometriosis are still unclear, endocrine, immunologic, pro-in&#xfb02;ammatory, and</span></p>
<p style="top:674.9pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pro-angiogenic processes are known to be involved in the development of endometriosis.</span></p>
<p style="top:687.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Considering the pharmacological effects of toxic animal-based medicinal materials on</span></p>
<p style="top:700.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">endometriosis and other diseases, the possible action mechanisms of toxic animal-based</span></p>
<p style="top:712.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">medicinal materials against endometriosis can be summarized as follows: induction of</span></p>
<p style="top:725.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptosis, antiangiogenesis effect, reduction of estrogen level, anti-in&#xfb02;ammatory action,</span></p>
<p style="top:737.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and suppression of cell adhesion and invasion (Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">).</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 of 21</span></p>
<p style="top:669.4pt;left:36.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:0.8pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">development of endometriosis. Considering the pharmacological effects of toxic animal-</span></p>
<p style="top:13.6pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">based medicinal materials on endometriosis and other diseases, the possible action </span></p>
<p style="top:26.5pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">mechanisms of toxic animal-based medicinal materials against endometriosis can be </span></p>
<p style="top:39.3pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">summarized as follows: induction of apoptosis, antiangiogenesis effect, reduction of </span></p>
<p style="top:52.2pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">estrogen level, anti-inflammatory action, and suppression of cell adhesion and invasion </span></p>
<p style="top:64.9pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">(Figure 3). </span></p>
<p style="top:319.8pt;left:542.0pt;line-height:10.0pt"><b><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></b></p>
<p style="top:335.6pt;left:94.0pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Figure 3. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Possible action mechanisms of toxic animal-based medicinal materials against endometriosis. </span></p>
<p style="top:359.3pt;left:188.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Toxic animal-based medicinal materials may cause unwanted side effects due to their </span></p>
<p style="top:372.1pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">toxic effects. Minimizing adverse events is an essential part of drug development. Even </span></p>
<p style="top:385.0pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">with the medicines that have been used based on historical experience, the types and </span></p>
<p style="top:397.8pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">frequency of adverse events must be identified. However, among the studies included in </span></p>
<p style="top:410.7pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">this review, 75% of the studies had no reports on side-effects, and three studies [37,42,45] </span></p>
<p style="top:423.4pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">reported that no side effects were observed after administration of herbal medicines </span></p>
<p style="top:436.2pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">containing Hirudo and Scolopendra [37], Scolopendra [45], and Scorpio [42]. However, it </span></p>
<p style="top:449.1pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">was not possible to find any information on what kind of events they were monitoring.  </span></p>
<p style="top:461.9pt;left:188.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">The number of participants who participated in the studies that reported no side </span></p>
<p style="top:474.8pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">effects was small. Since the known occurrence of adverse events was 5% to 10% [82,83], </span></p>
<p style="top:487.5pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">the findings of this study are not sufficient to support a conclusion that the administration </span></p>
<p style="top:500.3pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">of toxic animal-based medicinal materials upon the patients with endometriosis would </span></p>
<p style="top:513.2pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">result in no side effects. Even if the toxic animal-based medicinal materials have historical </span></p>
<p style="top:526.0pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">evidence, it is necessary to identify the existence, occurrence rate, and severity of adverse </span></p>
<p style="top:538.8pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">events through real data collection. A clinical study must be designed to report any </span></p>
<p style="top:551.6pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">adverse events, no matter how insignificant they may look. </span></p>
<p style="top:564.4pt;left:188.2pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">In addition, in order to identify the possible adverse events that can be caused by </span></p>
<p style="top:577.2pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">toxic animal-based medicinal materials, we searched other studies that reported adverse </span></p>
<p style="top:590.1pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">events after administering toxic animal-based medicinal materials. Among the studies </span></p>
<p style="top:602.9pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">included in this review, three studies [37,42,45] reported that no side effects were observed </span></p>
<p style="top:615.6pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">after administration of herbal medicines containing Hirudo and Scolopendra [37], </span></p>
<p style="top:628.5pt;left:166.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Scolopendra [45], and Scorpio [42], and that no adverse effects were reported following </span></p>
<img style="position:absolute;transform:matrix(.5083659,0,-0,.50789418,-241.50269,-38.038606)" src="data:image/jpeg;base64,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">
<p style="top:329.7pt;left:94.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 3.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Possible action mechanisms of toxic animal-based medicinal materials against endometriosis.</span></p>
<p style="top:351.4pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Toxic animal-based medicinal materials may cause unwanted side effects due to their</span></p>
<p style="top:363.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">toxic effects. Minimizing adverse events is an essential part of drug development. Even</span></p>
<p style="top:376.4pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with the medicines that have been used based on historical experience, the types and</span></p>
<p style="top:389.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">frequency of adverse events must be identi&#xfb01;ed. However, among the studies included in</span></p>
<p style="top:401.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">this review, 75% of the studies had no reports on side-effects, and three studies</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span></p>
<p style="top:414.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reported that no side effects were observed after administration of herbal medicines con-</span></p>
<p style="top:426.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">taining Hirudo and Scolopendra [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], Scolopendra [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], and Scorpio [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. However, it was</span></p>
<p style="top:439.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">not possible to &#xfb01;nd any information on what kind of events they were monitoring.</span></p>
<p style="top:451.7pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The number of participants who participated in the studies that reported no side</span></p>
<p style="top:464.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">effects was small. Since the known occurrence of adverse events was 5% to 10% [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">82</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">83</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">],</span></p>
<p style="top:476.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the &#xfb01;ndings of this study are not suf&#xfb01;cient to support a conclusion that the administration</span></p>
<p style="top:489.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of toxic animal-based medicinal materials upon the patients with endometriosis would</span></p>
<p style="top:502.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">result in no side effects. Even if the toxic animal-based medicinal materials have historical</span></p>
<p style="top:514.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">evidence, it is necessary to identify the existence, occurrence rate, and severity of adverse</span></p>
<p style="top:527.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">events through real data collection. A clinical study must be designed to report any adverse</span></p>
<p style="top:539.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">events, no matter how insigni&#xfb01;cant they may look.</span></p>
<p style="top:552.1pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In addition, in order to identify the possible adverse events that can be caused by</span></p>
<p style="top:564.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">toxic animal-based medicinal materials, we searched other studies that reported adverse</span></p>
<p style="top:577.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">events after administering toxic animal-based medicinal materials. Among the studies</span></p>
<p style="top:589.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">included in this review, three studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] reported that no side effects were ob-</span></p>
<p style="top:602.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">served after administration of herbal medicines containing Hirudo and Scolopendra [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">],</span></p>
<p style="top:614.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Scolopendra [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and Scorpio [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and that no adverse effects were reported following</span></p>
<p style="top:627.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the administration of herbal medicines containing Eupolyphaga. However, these &#xfb01;ndings</span></p>
<p style="top:640.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">are inconsistent with those of other studies. Hirudo is prohibited for pregnant women,</span></p>
<p style="top:652.7pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">patients with profuse menstruation or hemorrhagic tendency, patients with no blood stasis,</span></p>
<p style="top:665.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and weak patients because Hirudo is highly potent in breaking blood and expelling stasis,</span></p>
<p style="top:677.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">unblocking the meridian, and eliminating mass [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Zeng et al. reported gastrointestinal</span></p>
<p style="top:690.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">bleeding (1.9%) and cerebral hernia (0.9%) after the administration of herbal medicines</span></p>
<p style="top:702.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">containing Hirudo and</span><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Tabanus bivittatus</span></i><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> Matsumura in patients with acute intracerebral</span></p>
<p style="top:715.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">hemorrhage [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">84</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Historically, owing to its toxicity, Scolopendra has not been used at a</span></p>
<p style="top:727.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">high dosage, as its excessive use can damage healthy qi and cause early abortion [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">];</span></p>
<p style="top:740.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">therefore, it is prohibited for use in pregnant women and patients with blood de&#xfb01;ciency</span></p>
<p style="top:753.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">generating wind [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In one patient with chronic hepatitis B infection, hepatotoxicity was</span></p>
<p style="top:765.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">reported after the administration of herbal medicine containing Scolopendra [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">85</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. How-</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">16 of 21</span></p>
<p style="top:97.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ever, this herbal medicine contained not only Scolopendra but also the hepatotoxic Meliae</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Fructus and Rhei Radix et Rhizoma [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">85</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]; these toxic effects cannot be attributed solely to</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Scolopendra, but caution is needed when subjecting patients with chronic hepatitis B to</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Scolopendra treatment. In traditional Chinese medicine, Eupolyphaga is contraindicated</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">for pregnant women because it may induce early abortion owing to its blood-breaking</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and stasis- expelling ef&#xfb01;cacies, and it should be used with caution in patients with no</span></p>
<p style="top:172.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">blood stasis or patients with both blood de&#xfb01;ciency and blood stasis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Several studies</span></p>
<p style="top:185.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">have reported the side effects of Eupolyphaga. However, in a study where 21 HIV/AIDS</span></p>
<p style="top:198.0pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">patients were treated with a drug containing 20 g of Eupolyphaga twice a day for 4 months,</span></p>
<p style="top:210.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">no side effects or toxic reactions were reported [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">86</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Scorpion should be prohibited in</span></p>
<p style="top:222.9pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">patients with blood de&#xfb01;ciency generating wind, and should be used at a dose range of</span></p>
<p style="top:235.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">3&#x2013;5 g owing to its toxicity [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. There was one case of hepatotoxicity after administration</span></p>
<p style="top:248.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of herbal medicine containing Scorpio in a patient with chronic hepatitis B infection [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">85</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:260.6pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Taken together, the patient&#x2019;s conditions should be considered when administering toxic</span></p>
<p style="top:273.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">animal-based medicinal materials, and attention should be paid to the menstrual cycle</span></p>
<p style="top:285.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">during treatment with these materials, as they can cause excessive bleeding in patients</span></p>
<p style="top:298.4pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with menorrhagia. In addition, when administering these medicinal materials to women of</span></p>
<p style="top:310.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">childbearing age, the possibility of pregnancy should be assessed. Moreover, overuse of</span></p>
<p style="top:323.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">these medicinal materials should be avoided because it has been reported to be associated</span></p>
<p style="top:336.0pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">with hepatitis.</span></p>
<p style="top:348.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">This is the &#xfb01;rst study to review both preclinical and clinical studies investigating</span></p>
<p style="top:361.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the ef&#xfb01;cacy of toxic animal-based medicinal materials in the treatment of endometriosis.</span></p>
<p style="top:373.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Our analysis results suggested the possible therapeutic mechanisms of toxic animal-based</span></p>
<p style="top:386.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">medical materials against endometriosis and provided data as a reference for future transla-</span></p>
<p style="top:398.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tional studies. In addition, we included studies from major databases, such as PubMed and</span></p>
<p style="top:411.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Embase, and searched without language and date restrictions. However, there were some</span></p>
<p style="top:423.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">limitations in this review. First, as we used only the biopharmaceutical names as search</span></p>
<p style="top:436.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">terms, there is a possibility that potentially relevant articles not containing our search key</span></p>
<p style="top:449.0pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">words and phrases in the titles or abstracts were not included in our analysis. Second, the</span></p>
<p style="top:461.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">number of included studies was small. Third, it was dif&#xfb01;cult to determine whether the</span></p>
<p style="top:474.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">reported therapeutic effects were exerted by the toxic animal-based medicinal materials, as</span></p>
<p style="top:486.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">these materials were used concomitantly with other medicinal materials. Fourth, there were</span></p>
<p style="top:499.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">some factors that required attention in interpreting the study &#xfb01;ndings. Five of the clinical</span></p>
<p style="top:511.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies we reviewed were case series, and therefore the level of evidence was somewhat</span></p>
<p style="top:524.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">low. Seven RCTs did not provide their protocols and were without any description of</span></p>
<p style="top:536.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">their randomization or blinding methods. Furthermore, some studies used mifepristone or</span></p>
<p style="top:549.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">different types of herbal medicines rather than the conventional treatment of endometriosis</span></p>
<p style="top:562.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">as control, so caution is needed as one interprets the results of these studies. Some studies</span></p>
<p style="top:574.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">did not report side effects or what kind of important harms or unintended effects they</span></p>
<p style="top:587.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">observed. Therefore, even if some studies did not report side effects, it does not necessarily</span></p>
<p style="top:599.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">support the conclusion that toxic animal-based medicinal materials are safe to use. Lastly,</span></p>
<p style="top:612.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">endometriosis is diagnosed by ascertaining symptoms, undertaking examination, and</span></p>
<p style="top:624.6pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">performing laparoscopic surgery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">87</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Of the studies that were included in this review,</span></p>
<p style="top:637.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">only three [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] used laparoscopes to diagnose endometriosis. Other studies all re-</span></p>
<p style="top:649.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">lied on presumed diagnosis based on symptoms, examination, ultrasonography, and lab</span></p>
<p style="top:662.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">test results, without any classi&#xfb01;cation of endometriosis, which were the limitations of</span></p>
<p style="top:674.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">these studies.</span></p>
<p style="top:687.5pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Through this scoping review, we showed that toxic animal-based medicinal materials</span></p>
<p style="top:700.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">might be effective as a clinical treatment of endometriosis. However, because the number of</span></p>
<p style="top:712.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical studies included was small and the intervention and treatment goals were different,</span></p>
<p style="top:725.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the &#xfb01;ndings of this review are insuf&#xfb01;cient for establishing a standard for the application</span></p>
<p style="top:737.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of toxic animal-based medicinal materials as a treatment of endometriosis. In addition,</span></p>
<p style="top:750.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">although toxic animal-based medicinal materials have been shown to be effective against</span></p>
<p style="top:762.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">endometriosis in experimental studies, research on their speci&#xfb01;c therapeutic mechanisms</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">17 of 21</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">is still lacking. Therefore, evidence supporting the use of toxic animal-based medicinal</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">materials as a treatment of endometriosis is still limited, and further research is necessary.</span></p>
<p style="top:122.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The preclinical studies and clinical studies included in this review showed that the</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">most promising toxic animal-based medicinal material for endometriosis is likely to be</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Hirudo. As shown in Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">, Hirudo, Scolopendra, and Scorpio meet three categories</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of action mechanisms related to the progression of endometriosis. Eupolyphaga meets</span></p>
<p style="top:172.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">two categories. In addition, in the clinical studies shown in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Hirudo was included</span></p>
<p style="top:185.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in eight studies. Scolopendra, Eupolyphaga, and Scoprpio were included in &#xfb01;ve, four,</span></p>
<p style="top:197.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and one study, respectively. Thus, we assume that Hirudo might be the most prominent</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">candidate for treating endometriosis, among these toxic animal-based medicinal materials.</span></p>
<p style="top:222.9pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The preclinical studies demonstrated that Hirudo has activities inducing apoptosis and</span></p>
<p style="top:235.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibiting angiogenesis and in&#xfb02;ammation. Although these molecular mechanisms are</span></p>
<p style="top:248.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">closely related to the progression of endometriosis, the anti-endometriotic ef&#xfb01;cacy of</span></p>
<p style="top:260.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Hirudo was not fully demonstrated by a clinical study. In addition, there were no studies</span></p>
<p style="top:273.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">that used Hirudo only, so further study is needed to examine the treatment effect of Hirudo</span></p>
<p style="top:285.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">upon endometriosis. Scorpio, Scolopendra, and Eupholyphaga have been in clinical use,</span></p>
<p style="top:298.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">but their preclinical study is not suf&#xfb01;cient. Bee venom, Bufonis Venenum, and snake</span></p>
<p style="top:311.0pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">venom have been used in preclinical contexts, without any report of toxicity. As bee venom,</span></p>
<p style="top:323.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Bufonis Venenum, and snake venom may cause a serious adverse event, it is necessary to</span></p>
<p style="top:336.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">identify the adverse events and appropriate doses via preclinical studies.</span></p>
<p style="top:348.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In the future, the following steps would have to be taken in order to develop a new</span></p>
<p style="top:361.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">drug for endometriosis based on toxic animal-based medicinal materials. First, classical</span></p>
<p style="top:373.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">literature and medical records should be searched to obtain additional evidence supporting</span></p>
<p style="top:386.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the use of toxic animal-based medicinal materials in clinical setting. Next, extensive</span></p>
<p style="top:398.8pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">preclinical studies are needed to elucidate the mechanisms of endometriosis treatment that</span></p>
<p style="top:411.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">are frequently used in clinical practice. Research is needed not only on the therapeutic</span></p>
<p style="top:423.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mechanism of a single toxic animal-based medicinal material against endometriosis but</span></p>
<p style="top:436.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">also on the interaction between medicinal materials and decoctions that are traditionally</span></p>
<p style="top:449.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">used in combinations, including toxic animal-based medicinal materials. As they have toxic</span></p>
<p style="top:461.4pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">properties, quality control of single toxic animal-based medicinal materials is necessary,</span></p>
<p style="top:474.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and it is important to assess their safety and toxicity in future studies. Additional clinical</span></p>
<p style="top:486.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">trials should be conducted to establish the standardized as well as optimal dosage and</span></p>
<p style="top:499.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">dosing period of these medicinal materials.</span></p>
<p style="top:521.6pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">5. Conclusions</span></b></p>
<p style="top:537.1pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In this scoping review, preclinical and clinical studies investigating the ef&#xfb01;cacy of</span></p>
<p style="top:549.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">toxic animal-based medicinal materials against endometriosis did not provide suf&#xfb01;cient</span></p>
<p style="top:562.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">evidence to allow standardization of these materials as a treatment of endometriosis. How-</span></p>
<p style="top:574.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ever, the included studies have identi&#xfb01;ed toxic animal-based medical materials as potential</span></p>
<p style="top:587.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">treatments for endometriosis. In clinical studies, the administration of herbal medicines</span></p>
<p style="top:600.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">containing toxic animal-based medicinal materials alleviated symptoms such as dysmenor-</span></p>
<p style="top:612.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">rhea, infertility, endometrioma, and menstrual irregularities in patients with endometriosis,</span></p>
<p style="top:625.0pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with no side effects. In experimental studies, the main action mechanisms of toxic animal-</span></p>
<p style="top:637.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">based medicinal materials against endometriosis were identi&#xfb01;ed as induction of apoptosis,</span></p>
<p style="top:650.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antiangiogenesis effect, reduction of estrogen levels, and possibly, anti-in&#xfb02;ammatory ac-</span></p>
<p style="top:662.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">tion. Taken together, toxic animal-based medicinal materials are considered promising</span></p>
<p style="top:675.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to be developed as an effective treatment of endometriosis; however, additional studies</span></p>
<p style="top:687.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">are needed.</span></p>
<p style="top:712.2pt;left:166.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Author Contributions:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Conceptualization, S.-I.H. and J.-K.P.; methodology, S.-H.S. and J.-K.P.; data</span></p>
<p style="top:723.9pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">classi&#xfb01;cation and interpretation of data, S.-I.H., S.-H.S., Y.-J.Y., and K.-T.H.; writing&#x2014;original draft,</span></p>
<p style="top:735.7pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">S.-I.H.; writing&#x2014;review and editing, S.-H.S, K.-T.H, and J.-K.P.; supervision, J.-K.P.; project adminis-</span></p>
<p style="top:747.4pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">tration, J.-K.P.; funding acquisition, J.-K.P. All authors have read and agreed to the published version</span></p>
<p style="top:759.1pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of the manuscript.</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">18 of 21</span></p>
<p style="top:98.3pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Funding:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> This research was supported by the National Research Foundation of Korea (NRF) grant</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">funded by the Korean government (MSIT) (No. NRF-2019R1G1A1100022).</span></p>
<p style="top:127.7pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Institutional Review Board Statement:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Not applicable.</span></p>
<p style="top:145.4pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Informed Consent Statement:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Not applicable.</span></p>
<p style="top:163.1pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Data Availability Statement:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The data will be made available upon reasonable request.</span></p>
<p style="top:180.8pt;left:166.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Acknowledgments:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Picture of Hirudo, Scorpio, Scolopendra, and Eupolyphaga used in this review</span></p>
<p style="top:192.5pt;left:166.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">were prepared by the Koran Institute of Oriental Medicine in 2017, disclosed for open access under</span></p>
<p style="top:204.2pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Type 1 KOGL (Korea Open Government Licenses). The said copyright material can be download at</span></p>
<p style="top:215.9pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Korea Institute of Oriental Medicine,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://herba.kr/boncho/?m=list&amp;t=pics\T1\textquoteright</span></p>
<p style="top:227.6pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">free of charge.</span></p>
<p style="top:245.3pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Con&#xfb02;icts of Interest:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The authors declare that there are no con&#xfb02;ict of interest regarding the publica-</span></p>
<p style="top:257.0pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tion of this paper.</span></p>
<p style="top:278.7pt;left:36.0pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">References</span></b></p>
<p style="top:294.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Bulun, S.E.; Yilmaz, B.D.; Sison, C.; Miyazaki, K.; Bernardi, L.; Liu, S.; Kohlmeier, A.; Yin, P.; Milad, M.; Wei, J. Endometriosis.</span></p>
<p style="top:305.5pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Endocr. Rev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 40</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1048&#x2013;1079. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:317.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.</span></p>
<p style="top:317.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Vigan</span><span style="font-family:VnURWPalladioL,serif;font-size:8.9pt">&#xf2;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, P. Endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nat. Rev. Dis.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 4</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 9. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:328.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3.</span></p>
<p style="top:328.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Shafrir, A.L.; Farland, L.V.; Shah, D.K.; Harris, H.R.; Kvaskoff, M.; Zondervan, K.; Missmer, S.A. Risk for and consequences of</span></p>
<p style="top:340.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">endometriosis: A critical epidemiologic review.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Best Pract. Res. Clin. Obstet. Gynaecol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 51</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1&#x2013;15. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:351.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.</span></p>
<p style="top:351.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zondervan, K.T.; Becker, C.M.; Missmer, S.A. Endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> N. Engl. J. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 382</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1244&#x2013;1256. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:363.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5.</span></p>
<p style="top:363.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Falcone, T.; Flyckt, R. Clinical Management of Endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Obstet. Gynecol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 131</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 557&#x2013;571. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.</span></p>
<p style="top:374.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Peiris, A.N.; Chaljub, E.; Medlock, D. Endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> JAMA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 320</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2608. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:386.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.</span></p>
<p style="top:385.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Czyzyk, A.; Pod&#xfb01;gurna, A.; Szeliga, A.; Meczekalski, B. Update on endometriosis pathogenesis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Minerva Ginecol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 69</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:397.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">447&#x2013;461. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:409.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8.</span></p>
<p style="top:409.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Flores, I.; Rivera, E.; Ruiz, L.A.; Santiago, O.I.; Vernon, M.W.; Appleyard, C.B. Molecular pro&#xfb01;ling of experimental endometriosis</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">identi&#xfb01;ed gene expression patterns in common with human disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Fertil. Steril.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 87</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1180&#x2013;1199. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9.</span></p>
<p style="top:432.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Van Gorp, T.; Amant, F.; Neven, P.; Vergote, I.; Moerman, P. Endometriosis and the development of malignant tumours of the</span></p>
<p style="top:443.5pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pelvis. A review of literature.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Best Pract. Res. Clin. Obstet. Gynaecol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2004</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 349&#x2013;371. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:455.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10.</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Krupa, A.; Pada&#x142;a, O.; Putowski, M.; Konopelko, M.; Piasek, E. Available treatment methods for endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Educ. Health</span></i></p>
<p style="top:466.6pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sport.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 178&#x2013;184. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:478.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11.</span></p>
<p style="top:478.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis:</span></p>
<p style="top:489.6pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A committee opinion.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Fertil. Steril.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 101</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 927&#x2013;935. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:501.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">12.</span></p>
<p style="top:501.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Bina, F.; Soleymani, S.; Toliat, T.; Hajimahmoodi, M.; Tabarrai, M.; Abdollahi, M.; Rahimi, R. Plant-derived medicines for treatment</span></p>
<p style="top:512.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of endometriosis: A comprehensive review of molecular mechanisms.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pharmacol. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 139</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 76&#x2013;90. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:524.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">13.</span></p>
<p style="top:524.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Meresman, G.F.; G&#xf6;tte, M.; Laschke, M.W. Plants as source of new therapies for endometriosis: A review of preclinical and clinical</span></p>
<p style="top:535.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">studies.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Hum Reprod Update.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, dmaa039. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:547.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14.</span></p>
<p style="top:547.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zheng, W.; Wu, J.; Gu, J.; Weng, H.; Wang, J.; Wang, T.; Liang, X.; Cao, L. Modular Characteristics and Mechanism of Action of</span></p>
<p style="top:558.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Herbs for Endometriosis Treatment in Chinese Medicine: A Data Mining and Network Pharmacology&#x2013;Based Identi&#xfb01;cation.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Front.</span></i></p>
<p style="top:570.1pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 147. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">15.</span></p>
<p style="top:581.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Han, Y.F.; Hou, L.H.; Zhou, Y.J.; Wu, X.K. A survey of TCM treatment for endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> J. Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 29</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 64&#x2013;70.</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">16.</span></p>
<p style="top:604.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Bae, K.Y.; Rhyu, M.R.; Roh, J.J.; Kim, D.I. Vasodilatory Activities and Safety of the Water Extracts of Three Medicinal Remedy in</span></p>
<p style="top:616.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Species of Insects.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Korean Obstet. Gynecol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 114&#x2013;124.</span></p>
<p style="top:627.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">17.</span></p>
<p style="top:627.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sha, B.; Zhu, W.H. On the Application of Insect Medicine in Rheumatism from the Inheritance of Menghe Medical School.</span></p>
<p style="top:639.2pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rheumatism Arthritis</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 64&#x2013;65.</span></p>
<p style="top:650.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18.</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, W.P.; Zou, J.; Wu, W. Case Records Illustration of Professor WU Wei Who has Used Insect Medicine to Treat Kidney</span></p>
<p style="top:662.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Sichuan Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 85&#x2013;87.</span></p>
<p style="top:673.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19.</span></p>
<p style="top:673.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Chen, Y.; Ji, L.; Wang, M.; Li, M.; Cui, S. Research Progress in the Application of Insect Medicinals in Gynecological Diseases.</span></p>
<p style="top:685.2pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Shandong J. Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1022&#x2013;1025.</span></p>
<p style="top:696.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20.</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, J.H.; Wang, T.Z.; Jiang, D.Y. JIANG De-you&#x2019;s experience in treating cardiovascular and cerebrovascular diseases with</span></p>
<p style="top:708.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">insect drug.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> China J. Tradit. Chin. Med. Pharm.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3962&#x2013;3965.</span></p>
<p style="top:719.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21.</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Klupczynska, A.; Pawlak, M.; Kokot, Z.J.; Matysiak, J. Application of Metabolomic Tools for Studying Low Molecular-Weight</span></p>
<p style="top:731.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fraction of Animal Venoms and Poisons.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 306. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:742.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22.</span></p>
<p style="top:742.8pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Bordon, K.C.F.; Cologna, C.T.; Fornari-Baldo, E.C.; Pinheiro-J</span><span style="font-family:VnURWPalladioL,serif;font-size:8.9pt">&#xfa;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">nior, E.L.; Cerni, F.A.; Amorim, F.G.; Anjolette, F.A.P.; Cordeiro, F.A.;</span></p>
<p style="top:754.3pt;left:57.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wiezel, G.A.; Cardoso, I.A.; et al. From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in</span></p>
<p style="top:765.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Discovery.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1132. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">19 of 21</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23.</span></p>
<p style="top:98.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chatterjee, B. Animal Venoms have Potential to Treat Cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Curr. Top. Med. Chem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2555&#x2013;2566. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:109.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">24.</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ravi, K.U. Use of Animal Venom Peptides/Toxins in Cancer Therapeutics.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Biomed. Eng.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1&#x2013;26. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:121.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">25.</span></p>
<p style="top:121.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Choi, G. Animal-based medicinal materials in the pharmacopeias of Northeast Asian countries.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Korean Herb. Med. Inf.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:132.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">203&#x2013;230. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:144.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Herbology editorial committee of Korean medicine schools.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Herbology</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">; Yeonglimsa: Seoul, Korea, 2012; pp. 469&#x2013;471, 546&#x2013;548.</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27.</span></p>
<p style="top:155.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lim, E.-M.; Kwon, K.-R.; Lee, Y.-H. Effects of Bee Venom Acupuncture on Surgically Induced Endometriosis Rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Pharmacopunct.</span></i></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 21&#x2013;32.</span></p>
<p style="top:178.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">28.</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Nasu, K.; Nishida, M.; Ueda, T.; Takai, N.; Bing, S.; Narahara, H.; Miyakawa, I. Bufalin induces apoptosis and the G0/G1 cell</span></p>
<p style="top:190.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">cycle arrest of endometriotic stromal cells: A promising agent for the treatment of endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Mol. Hum. Reprod.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">817&#x2013;823. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:213.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">29.</span></p>
<p style="top:213.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Cho, Y.J.; Lee, J.E.; Park, M.J.; O&#x2019;Malley, B.W.; Han, S.J. Bufalin suppresses endometriosis progression by inducing pyroptosis and</span></p>
<p style="top:224.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">apoptosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Endocrinol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 237</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 255&#x2013;269. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:236.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30.</span></p>
<p style="top:236.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Liu, Y.L. Investigate the role of &#x201c;Pingchongjiangnifang&#x201d; of the</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> culture of human endometrial stromal cells. Master&#x2019;s</span></p>
<p style="top:247.9pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Thesis, Jiangxi University of Traditional Chinese Medicine, Nanchang, China, 1 May 2014.</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">31.</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Xu, Z. Data Mining and Experimental Research on the Treatment of Endometriosis Dysmenorrhea by Professor Si Tuyi, a Famous</span></p>
<p style="top:270.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chinese Medicine Practitioner. Ph.D. Thesis, Guangzhou University of Chinese Medicine, Guangzhou, China, 1 April 2018.</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">32.</span></p>
<p style="top:282.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liu, H.; Sun, X.; Zhao, Y.; Xia, M.; Wang, C. Anti-angiogenesis effect and mechanism study of Huangzhi Neiyi capsule in a rat</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">endometriosis model.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Int. Med. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 48</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 300060519899767. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33.</span></p>
<p style="top:305.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, T.F. The Effect of Wudanwan Modi&#xfb01;ed Formula on Rat Endometriosis Model. Master&#x2019;s Thesis, Beijing University of</span></p>
<p style="top:316.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chinese Medicine, Beijing, China, 1 May 2005.</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">34.</span></p>
<p style="top:328.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zhang, Q. Effects of Disintegrin of</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Gloydius Brevicaudus</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Venom on Endometriosis of Rat and Its Mechanism. Master&#x2019;s Thesis,</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fujian Medical University, Fuzhou, China, 1 June 2015.</span></p>
<p style="top:351.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">35.</span></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wu, X. Treatment of 60 cases of endometriosis by dissolving blood and removing blood stasis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Shaanxi Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1993</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:362.9pt;left:57.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 530.</span></p>
<p style="top:374.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">36.</span></p>
<p style="top:374.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhang, L. Professor Wang Ziyu&#x2019;s Experience in Treating Endometriosis Dysmenorrhea. Master&#x2019;s Thesis, Beijing University of</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chinese Medicine, Beijing, China, 1 May 2007.</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">37.</span></p>
<p style="top:397.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Xu, Y.; Su, J.; Cao, H. Shuizhi Tongluo Capsule in the treatment of 52 cases of endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Hebei Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 29</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 797.</span></p>
<p style="top:409.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">38.</span></p>
<p style="top:408.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zhang, X.; Wang, W. Clinical analysis of 78 cases of endometriosis treated with Quyu Jiedu Xiaozheng Decoction.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Mod. Chin.</span></i></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 27</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 18&#x2013;19.</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">39.</span></p>
<p style="top:432.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Feng, D. Xiaoyi Zhuyun Decoction in the treatment of 35 cases of endometriotic infertility.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Res. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 27</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 36&#x2013;37.</span></p>
<p style="top:443.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">40.</span></p>
<p style="top:443.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Han, D.; Yu, F.; Wang, H. Clinical observation on 78 cases of endometriosis treated with traditional Chinese medicine leech.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Chin.</span></i></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Coal Ind. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 303&#x2013;304.</span></p>
<p style="top:466.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">41.</span></p>
<p style="top:466.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhang, X.; Dong, L.; Wang, Q. Treatment of 45 cases of endometriosis with Quyu Jiedu Xiaozheng Decoction.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Shaanxi J. Tradit.</span></i></p>
<p style="top:478.0pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 30</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 260&#x2013;261.</span></p>
<p style="top:489.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">42.</span></p>
<p style="top:489.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lin, H.; Xiao, W.; He, X.; Peng, J. Observation on the clinical ef&#xfb01;cacy of Quanxie Foshou Powder in the treatment of endometriosis.</span></p>
<p style="top:501.0pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lishizhen Med. Mater. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2819&#x2013;2820.</span></p>
<p style="top:512.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">43.</span></p>
<p style="top:512.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Meng, W.; Xu, Y. Clinical observation of 156 cases of endometriosis treated with traditional Chinese medicine leech.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Changchun</span></i></p>
<p style="top:524.0pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Univ. Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 28</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 128&#x2013;129.</span></p>
<p style="top:535.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">44.</span></p>
<p style="top:535.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Guo, M.; Qi, S.; Niu, G.; Liu, Z. Bushen Quyu Decoction combined with desogestrel and ethinyl estradiol tablets in the treatment</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of 48 cases of infertility with endometriosis after laparoscopic surgery.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 26</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 26&#x2013;28.</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">45.</span></p>
<p style="top:558.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Liu, H. Self-Made Dysmenorrhea Particles in the Treatment of Dysmenorrhea Caused by Endometriosis (Qi and Blood Stasis</span></p>
<p style="top:570.0pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Type) the Safety and Clinical Research. Master&#x2019;s Thesis, Changchun University of Traditional Chinese Medicine, Changchun,</span></p>
<p style="top:581.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">China, 1 March 2017.</span></p>
<p style="top:593.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">46.</span></p>
<p style="top:593.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Yi, S.; Liu, L. The clinical study of Xiaoyizhitong Decoction combined with gestrinone in the treatment of endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Chin.</span></i></p>
<p style="top:604.6pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Med. Guide</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 215&#x2013;216.</span></p>
<p style="top:616.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">47.</span></p>
<p style="top:616.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ko, C.R.; Ku, N.P.; Seol, S.S. A Comparative Study on the Traditional Medicine Policies between Korea and China: Focused on the</span></p>
<p style="top:627.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Second Korean Medicine Development Plan and the 12.5 Traditional Chinese Medicine Development Plan.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Korea Technol. Innov.</span></i></p>
<p style="top:639.1pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Soc.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 421&#x2013;447.</span></p>
<p style="top:650.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">48.</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wei, W.L.; Hou, J.J.; Wang, X.; Yu, Y.; Li, H.J.; Li, Z.W.; Feng, Z.J.; Qu, H.; Wu, W.Y.; Guo, D.A. Venenum bufonis: An overview</span></p>
<p style="top:662.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of its traditional use, natural product chemistry, pharmacology, pharmacokinetics and toxicology.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Ethnopharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 237</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:673.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">215&#x2013;235. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:685.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">49.</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Jang, S.; Kim, K.H. Clinical Effectiveness and Adverse Events of Bee Venom Therapy: A Systematic Review of Randomized</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Controlled Trials.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 558. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:708.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">50.</span></p>
<p style="top:708.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wei, J.M.; Zhu, M.W.; Zhang, Z.T.; Jia, Z.G.; He, X.D.; Wan, Y.L.; Wang, S.; Xiu, D.R.; Tang, Y.; Li, J.; et al. A multicenter, phase III</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">trial of hemocoagulase Agkistrodon: Hemostasis, coagulation, and safety in patients undergoing abdominal surgery.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Chin. Med. J.</span></i></p>
<p style="top:731.2pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 123</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 589&#x2013;593. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:742.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">51.</span></p>
<p style="top:742.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Xu, Y.Y.; Ma, X.H.; Zhang, S.J. Hemocoagulase agkistrodon-induced anaphylactic shock: A case report and literature review.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Int.</span></i></p>
<p style="top:754.2pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Clin. Pharmacol. Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 54</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 129&#x2013;134. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">20 of 21</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">52.</span></p>
<p style="top:98.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Miao, Q.; Bi, L.L.; Li, X.; Miao, S.; Zhang, J.; Zhang, S.; Yang, Q.; Xie, Y.H.; Zhang, J.; Wang, S.W. Anticancer effects of bufalin on</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">human hepatocellular carcinoma HepG2 cells: Roles of apoptosis and autophagy.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1370&#x2013;1382. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:121.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">53.</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Qi, F.; Li, A.; Inagaki, Y.; Kokudo, N.; Tamura, S.; Nakata, M.; Tang, W. Antitumor activity of extracts and compounds from the</span></p>
<p style="top:132.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">skin of the toad</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Bufo bufo gargarizans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cantor.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. Immunopharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 342&#x2013;349. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:144.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">54.</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Liu, L.; Chen, B.A.; Qin, S.K. Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplan-</span></p>
<p style="top:155.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tation model nude mice.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Chin. J. Integr. Tradit. West. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 31</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 67&#x2013;72.</span></p>
<p style="top:167.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">55.</span></p>
<p style="top:167.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lee, J.A.; Son, M.J.; Choi, J.; Jun, J.H.; Kim, J.I.; Lee, M.S. Bee venom acupuncture for rheumatoid arthritis: A systematic review of</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">randomised clinical trials.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMJ Open</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 4</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e006140. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">56.</span></p>
<p style="top:190.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Gazerani, P.; Cairns, B.E. Venom-based biotoxins as potential analgesics.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Expert Rev. Neurother.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1261&#x2013;1274. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:201.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">57.</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Xi, S.; Gong, Y.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Essentials of Chinese Materia Medica and Medical Formulas: New Century Traditional Chinese Medicine</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">; Elsevier</span></p>
<p style="top:213.3pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(Academic Press): London, UK, 2017; pp. 246&#x2013;319.</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">58.</span></p>
<p style="top:224.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lu, J.; Chen, X.; Xu, X.; Liu, J.; Zhang, Z.; Wang, M.; Li, X.; Chen, H.; Zhao, D.; Wang, J.; et al. Active polypeptides from Hirudo</span></p>
<p style="top:236.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">inhibit endothelial cell in&#xfb02;ammation and macrophage foam cell formation by regulating the LOX-1/LXR-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">/ABCA1 pathway.</span></p>
<p style="top:247.9pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biomed. Pharmacother.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 115</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 108840. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">59.</span></p>
<p style="top:259.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Dong, H.; Ren, J.X.; Wang, J.J.; Ding, L.S.; Zhao, J.J.; Liu, S.Y.; Gao, H.M. Chinese Medicinal Leech: Ethnopharmacology,</span></p>
<p style="top:270.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phytochemistry, and Pharmacological Activities.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Evid.-Based Complement. Altern. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 7895935. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">60.</span></p>
<p style="top:282.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wu, Q.; Guo, J.; Lu, H.; Kong, Q. Impacts of leech hirudo and blister beetle mylabris on the angiogenesis of chick chorioallantonic</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">membrance.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> World J. Integr. Tradit. West. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 855&#x2013;857.</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">61.</span></p>
<p style="top:305.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Guo, Y.; Tian, X.; Xiao, Z. Study on inhibition effects of freeze-thawing leech extract on HepG2 cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Chin. J. Inf. Tradit. Chin. Med.</span></i></p>
<p style="top:316.9pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 30&#x2013;31.</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">62.</span></p>
<p style="top:328.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Xiao, Y.S.; Liao, F.S.; Zhao, Z.D.; Zuo, A.R.; Zhu, D.C. Study on inhibitory functions of leech extract on HL60 cells</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vitro</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">experiment.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Jiangxi Univ. Tradit. Chin. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 25</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 63&#x2013;66.</span></p>
<p style="top:351.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">63.</span></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sig, A.K.; Guney, M.; Uskudar Guclu, A.; Ozmen, E. Medicinal leech therapy-an overall perspective.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Integr. Med. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:362.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">337&#x2013;343. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">64.</span></p>
<p style="top:374.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lee, W.; Lee, J.; Kulkarni, R.; Kim, M.A.; Hwang, J.S.; Na, M.; Bae, J.S. Antithrombotic and antiplatelet activities of small-molecule</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">alkaloids from Scolopendra subspinipes mutilans.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 21956. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">65.</span></p>
<p style="top:397.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Park, Y.J.; Lee, H.Y.; Jung, Y.S.; Park, J.S.; Hwang, J.S.; Bae, Y.S. Antimicrobial peptide scolopendrasin VII, derived from the</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">centipede</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Scolopendra subspinipes mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, stimulates macrophage chemotaxis via formyl peptide receptor 1.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMB Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 48</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">479&#x2013;484. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">66.</span></p>
<p style="top:431.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Park, J.H.; Lee, S.R. Anti-in&#xfb02;ammatory activities of</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Scolopendra subspinipes mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in RAW 264.7 cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Nutr. Health</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 51</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:443.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">323. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:455.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">67.</span></p>
<p style="top:454.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zheng, L.; He, H.; Shen, X.; Sun, Y. Centipede</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Scolopendra</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> suppresses cell growth in human epidermoid carcinoma cell A431.</span></p>
<p style="top:466.5pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bangladesh J. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 299. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:478.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">68.</span></p>
<p style="top:477.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ma, W.; Liu, R.; Qi, J.; Zhang, Y. Extracts of centipede</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Scolopendra subspinipes mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> induce cell cycle arrest and apoptosis in</span></p>
<p style="top:489.5pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A375 human melanoma cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncol. Lett.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 414&#x2013;420. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:501.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">69.</span></p>
<p style="top:500.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ma, W.; Zhang, D.; Zheng, L.; Zhan, Y.; Zhang, Y. Potential roles of Centipede</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Scolopendra</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> extracts as a strategy against</span></p>
<p style="top:512.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">EGFR-dependent cancers.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Am. J. Transl. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 39&#x2013;52.</span></p>
<p style="top:524.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">70.</span></p>
<p style="top:524.0pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hwang, L.; Ko, I.G.; Jin, J.J.; Kim, S.H.; Kim, C.J.; Jeon, J.W.; Han, J.H.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Scolopendra subspinipes mutilans</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Extract Suppresses</span></p>
<p style="top:535.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">In&#xfb02;ammatory and Neuropathic Pain In Vitro and In Vivo.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Evid.-Based Complement. Altern. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 5057372. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">71.</span></p>
<p style="top:558.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, F.X.; Wu, N.; Wei, J.T.; Liu, J.; Zhao, J.; Ji, A.G.; Lin, X.K. A novel protein from</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Eupolyphaga sinensis</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> inhibits adhesion,</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">migration, and invasion of human lung cancer A549 cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochem. Cell Biol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 91</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 244&#x2013;251. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">72.</span></p>
<p style="top:581.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zhang, Y.; Zhan, Y.; Zhang, D.; Dai, B.; Ma, W.; Qi, J.; Liu, R.; He, L.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Eupolyphaga sinensis</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Walker displays inhibition on</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">hepatocellular carcinoma through regulating cell growth and metastasis signaling.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 4</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 5518. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">73.</span></p>
<p style="top:604.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhan, Y.; Zhang, H.; Liu, R.; Wang, W.; Qi, J.; Zhang, Y.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Eupolyphaga sinensis</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Walker ethanol extract suppresses cell growth and</span></p>
<p style="top:616.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">invasion in human breast cancer cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Integr. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 102&#x2013;112. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:627.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">74.</span></p>
<p style="top:627.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ge, G.F.; Yu, C.H.; Yu, B.; Shen, Z.H.; Zhang, D.L.; Wu, Q.F. Antitumor effects and chemical compositions of</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Eupolyphaga sinensis</span></i></p>
<p style="top:639.1pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Walker ethanol extract.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Ethnopharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 141</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 178&#x2013;182. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:650.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">75.</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liu, H.; Yan, Y.; Zhang, F.; Wu, Q. The immuno-enhancement effects of tubiechong</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (Eupolyphaga sinensis)</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> lyophilized powder in</span></p>
<p style="top:662.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cyclophosphamide-induced immunosuppressed mice.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Immunol. Investig.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 48</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 844&#x2013;859. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">76.</span></p>
<p style="top:673.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Shoukry, N.M.; Salem, M.L.; Teleb, W.K.; Abdel Daim, M.M.; Abdel-Rahman, M.A. Antinociceptive, antiin&#xfb02;ammatory, and</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">antipyretic effects induced by the venom of Egyptian scorpion</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Androctonus amoreuxi</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Basic Appl. Zool.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 81</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 56. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:696.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">77.</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Tran, T.V.; Hoang, A.N.; Nguyen, T.T.T.; Phung, T.V.; Nguyen, K.C.; Osipov, A.V.; Ivanov, I.A.; Tsetlin, V.I.; Utkin, Y.N. Anticoag-</span></p>
<p style="top:708.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ulant activity of low-molecular weight compounds from</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Heterometrus laoticus</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> scorpion venom.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 343. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:731.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">78.</span></p>
<p style="top:731.1pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Yan, Y.Q.; Xie, J.; Wang, J.F.; Shi, Z.F.; Zhang, X.; Du, Y.P.; Zhao, X.C. Scorpion inhibits epithelial-mesenchymal transition and</span></p>
<p style="top:742.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">metastasis of hepatocellular carcinoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Exp. Biol. Med. (Maywood)</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 243</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 645&#x2013;654. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:754.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">79.</span></p>
<p style="top:754.1pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Kwon, K.B.; Kim, E.K.; Lim, J.G.; Jeong, E.S.; Shin, B.C.; Jeon, Y.S.; Kim, K.S.; Seo, E.A.; Ryu, D.G. Molecular mechanisms of</span></p>
<p style="top:765.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">apoptosis induced by Scorpio water extract in human hepatoma HepG2 cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> World J. Gastroenterol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 943&#x2013;947. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>


<p style="top:53.2pt;left:35.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Toxins</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 145</span></p>
<p style="top:53.2pt;left:532.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">21 of 21</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">80.</span></p>
<p style="top:98.3pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Al-Asmari, A.K.; Riyasdeen, A.; Islam, M. Scorpion Venom Causes Upregulation of p53 and Downregulation of Bcl-x(L) and BID</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Protein Expression by Modulating Signaling Proteins Erk(1/2) and STAT3, and DNA Damage in Breast and Colorectal Cancer</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cell Lines.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Integr. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 271&#x2013;281. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">81.</span></p>
<p style="top:132.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wang, Y.; Li, K.; Han, S.; Tian, Y.H.; Hu, P.C.; Xu, X.L.; He, Y.Q.; Pan, W.T.; Gao, Y.; Zhang, Z.; et al. Chlorotoxin targets ER</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">/VASP</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">signaling pathway to combat breast cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1679&#x2013;1693. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">82.</span></p>
<p style="top:155.7pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of</span></p>
<p style="top:167.3pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">prospective studies.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> JAMA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1998</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 279</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1200&#x2013;1205. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:178.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">83.</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Coleman, J.J.; Pontefract, S.K. Adverse drug reactions.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Clin. Med. (Lond.)</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 481&#x2013;485. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">84.</span></p>
<p style="top:190.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zeng, L.; Tang, G.; Wang, J.; Zhong, J.; Xia, Z.; Li, J.; Chen, G.; Zhang, Y.; Luo, S.; Huang, G.; et al. Safety and ef&#xfb01;cacy of herbal</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">medicine for acute intracerebral hemorrhage (CRRICH): A multicentre randomised controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMJ Open</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e024932.</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">85.</span></p>
<p style="top:224.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Yuen, M.F.; Tam, S.; Fung, J.; Wong, D.K.; Wong, B.C.; Lai, C.L. Traditional Chinese medicine causing hepatotoxicity in patients</span></p>
<p style="top:236.4pt;left:57.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">with chronic hepatitis B infection: A 1-year prospective study.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Aliment. Pharmacol. Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1179&#x2013;1186. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:247.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">86.</span></p>
<p style="top:247.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wei, J.A.; Sun, L.M.; Chen, Y.X. Effects of Ailing Granule on immuno-reconstruction in HIV/AIDS patients.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Chin. J. Integr. Tradit.</span></i></p>
<p style="top:259.4pt;left:57.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">West. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 26</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 319&#x2013;321.</span></p>
<p style="top:270.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">87.</span></p>
<p style="top:270.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Johnson, N.P.; Hummelshoj, L.; Adamson, G.D.; Keckstein, J.; Taylor, H.S.; Abrao, M.S.; Bush, D.; Kiesel, L.; Tamimi, R.; Sharpe-</span></p>
<p style="top:282.4pt;left:57.2pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Timms, K.L.; et al. World Endometriosis Society consensus on the classi&#xfb01;cation of endometriosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Hum. Reprod.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 32</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 315&#x2013;324.</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>

</div>
